{"SLR NAME":"Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review, meta-analysis and meta-regression","References":[{"title1":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","References":[{"title2":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","References":[]},{"title2":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","References":[{"title3":"Delayed decrease of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection"},{"title3":"Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza"},{"title3":"Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the &quot;PROTECT&quot; phase of the pandemic response"},{"title3":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis"},{"title3":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California"},{"title3":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand"},{"title3":"An epidemiological study of 1348 cases of pandemic H1N1 influenza admitted to Singapore hospitals from July to September 2009"},{"title3":"Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009"},{"title3":"Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China"},{"title3":"Concurrent comparison of epidemiology, clinical presentation outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and seasonal influenza A virus infection"},{"title3":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus"},{"title3":"Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus"},{"title3":"The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza"},{"title3":"Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome"},{"title3":"Hark back: passive immunotherapy for influenza and other serious infections"},{"title3":"Treatment of Argentine hemorrhagic fever"},{"title3":"Parvovirus B19 infection in pediatric transplant patients"},{"title3":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza"},{"title3":"Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic"},{"title3":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus"},{"title3":"The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment"},{"title3":"Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection"},{"title3":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009"},{"title3":"Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR"},{"title3":"Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice"},{"title3":"Acute renal impairment in coronavirus-associated severe acute respiratory syndrome"},{"title3":"The infection attack rate and severity of 2009 pandemic influenza (H1N1) in Hong Kong"},{"title3":"Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence"},{"title3":"Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China"},{"title3":"Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts"},{"title3":"Identification of influenza A nucleoprotein as an antiviral target"},{"title3":"Host defense mechanisms against influenza virus: interaction of influenza virus with murine macrophages in vitro"},{"title3":"Neutralization of human respiratory syncytial virus infectivity by antibodies low molecular weight compounds targeted against the fusion (F) glycoprotein"}]},{"title2":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand","References":[{"title3":"Pandemic (H1N1) 2009. Influenza update- 10 September 2010."},{"title3":"Australian Influenza Surveillance Report No.41, 2010"},{"title3":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand"},{"title3":"Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience"},{"title3":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration"},{"title3":"3101.0 - Australian Demographic statistics, March 2010 "},{"title3":"National population estimates, 2010"},{"title3":"Mortality associated with influenza and respiratory syncytial virus in the United States"},{"title3":"Pandemic (H1N1) 2009 influenza (&quot;swine flu&quot;) in Australian and New Zealand intensive care"},{"title3":"3201.0 - Population by Age and Sex, Australian States and Territories"},{"title3":"Pandemic (H1N1) 2009"},{"title3":"Critically ill patients with 2009 influenza A(H1N1) infection in Canada"},{"title3":"Critically Ill patients with 2009 influenza A(H1N1) in Mexico"},{"title3":"Rescue therapy in adult and pediatric patients with pH1N1 influenza infection: a tertiary center intensive care unit experience from April to October 2009"},{"title3":"Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere"},{"title3":"Hospitalized patients with 2009 H1N1 influenza infection: the Mayo Clinic experience"},{"title3":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California"},{"title3":"Severe respiratory disease concurrent with the circulation of H1N1 influenza"},{"title3":"Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain"},{"title3":"Severe 2009 H1N1 influenza in pregnant and postpartum women in California"},{"title3":"Factors associated with severe disease in hospitalised adults with pandemic (H1N1) 2009 in Spain"},{"title3":"Public Health Surveillance in New Zealand Influenza weekly update - 2010/39: 3 October 2010"},{"title3":"New Zealand Ministry of health Pandemic Influenza H1N12009 - Update 2011"},{"title3":"Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009"},{"title3":"Seroprevalence of the 2009 influenza A (H1N1) pandemic in New Zealand. 2010"},{"title3":"Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009"},{"title3":"Safety and effectiveness of a 2009 H1N1 vaccine in Beijing"},{"title3":"Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection"}]},{"title2":"Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome","References":[]},{"title2":"Critically ill patients with 2009 influenza A(H1N1) in Mexico","References":[]},{"title2":"Critically ill patients with 2009 influenza A(H1N1) infection in Canada","References":[{"title3":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model"},{"title3":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses"},{"title3":"Immunogenicity and protective efficacy of influenza vaccination"},{"title3":"Determinants of immunity to influenza infection in man"},{"title3":"Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection"},{"title3":"Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013"},{"title3":"Critically ill patients with 2009 influenza A(H1N1) infection in Canada"},{"title3":"Serological diagnosis of influenza by haemagglutination inhibition testing"},{"title3":"Host adaptive immunity deficiency in severe pandemic influenza"},{"title3":"Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study"},{"title3":"Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations"},{"title3":"Serum and mucosal antibodies fail as prognostic markers during critical influenza A infection"},{"title3":"Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome"},{"title3":"The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness"},{"title3":"Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores"},{"title3":"Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection"},{"title3":"Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia"},{"title3":"Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes"},{"title3":"Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain"},{"title3":"Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States"},{"title3":"Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis"}]},{"title2":"APACHE II: a severity of disease classification system","References":[]},{"title2":"PRISM III: an updated pediatric risk of mortality score","References":[]},{"title2":"MERS-CoV: clinical decision making support for treatment","References":[]},{"title2":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","References":[{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV):update (26 May 2014)"},{"title3":"Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do"},{"title3":"Treatment of MERS-CoV: decision support tool v.1.0"},{"title3":"State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans"},{"title3":"Hyperimmune iv immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a(H1N1) infection"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"SARS: systematic review of treatment effects"},{"title3":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital"},{"title3":"The management of coronavirus infections with particular reference to SARS"},{"title3":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement"},{"title3":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the effectiveness of convalescent plasma for the treatment of severe acute respiratory infections of viral aetiology: a systematic review. PROSPERO 2013CRD42013005091"},{"title3":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011"},{"title3":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses"},{"title3":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective"},{"title3":"Use of serum in the treatment of influenza-pneumonia"},{"title3":"Treatment of influenza with injections of blood from convalescents"},{"title3":"Treatment of influenza pneumonia with serum from convalescents"},{"title3":"Treatment of influenza pneumonia by use of convalescent human serum"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Clinical research during a public health emergency: a systematic review of severe pandemic influenza management"},{"title3":"Successful treatment of avian influenza with convalescent plasma"},{"title3":"Convalescent plasma for prophylaxis and treatment of severe pandemic influenza A (H1N1) 2009 infection: Case reports"},{"title3":"Treatment of severe acute respiratory syndrome with convalescent plasma"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula"},{"title3":"Letter to the editor"},{"title3":"Treatment of severe acute respiratory syndrome with convalescent plasma, author reply"},{"title3":"Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area"},{"title3":"Treatment of influenzal pneumonia with plasma of convalescent patients"},{"title3":"Treatment of influenzal pneumonia by the use of convalescent human serum"},{"title3":"Human serum in influenza"},{"title3":"Clinical characteristics of 26 human cases of highly pathogenic avian 36]influenza A (H5N1) virus infection in China"},{"title3":"Retrospective study on collecting convalescent donors's plasma in treatment of patients with pandemic influenza A (H1N1) virus infection"},{"title3":"Human serum in the treatment of influenza bronchopneumonia"},{"title3":"Convalescent serum in treatment of influenza"},{"title3":"Convalescent serum in the prevention and treatment of influenza"},{"title3":"Plasma therapy in influenza"},{"title3":"Report of influenza treated with serum from recovered cases"},{"title3":"Convalescent serum in the treatment of influenza pneumonia"},{"title3":"The use of the serum of convalescents in the treatment of influenza pneumonia: A summary of the results in a series of one hundred and one cases"},{"title3":"Advances in clinical diagnosis and treatment of severe acute respiratory syndrome"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Serum treatment of postinfluenzal bronchopneumonia"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Treatment of Severe Pandemic Influenza A/H1N1 Infection"},{"title3":"Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?"}]},{"title2":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","References":[]},{"title2":"End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease","References":[]},{"title2":"Association of oseltamivir treatment with virus shedding, illness, and household transmission of influenza viruses","References":[]},{"title2":"Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","References":[]}]},{"title1":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","References":[{"title2":"Dexamethasone in hospitalized patients with Covid-19","References":[{"title3":"Efficacy and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis"},{"title3":"Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients"},{"title3":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients"},{"title3":"Remdesivir strongly binds to RNA-dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: indication from molecular modeling and simulations"},{"title3":"Remdesivir for the treatment of Covid-19 - final report"},{"title3":"Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial"},{"title3":"Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results"},{"title3":"Early use of remdesivir and risk of disease progression in hospitalized patients with mild to moderate COVID-19"},{"title3":"Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study"},{"title3":"Early remdesivir to prevent progression to severe Covid-19 in outpatients"},{"title3":"Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant"},{"title3":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern"},{"title3":"Ministerio de Sanidad - Profesionales - Cuadro de mando resumen de datos de vacunacion s.f."},{"title3":"Informe de Posicionamiento Terapeutico de remdesivir (Veklury ) en el tratamiento de la COVID-19 s.f.:12."},{"title3":"Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients"},{"title3":"Association between city-wide lockdown and COVID-19 hospitalization rates in multigenerational households in New York City"},{"title3":"Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19"},{"title3":"A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19"},{"title3":"COVID-19 as an acute inflammatory disease"}]},{"title2":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 : final report. N. Engl. J. Med.10.1056/NEJMoa2007764 (2020).","References":[]},{"title2":"Repurposed antiviral drugs for COVID-19 : interim WHO SOLIDARITY trial results. WHO Solidarity Trial Consortium","References":[]},{"title2":"Study assessing the safety, tolerability, pharmacokinetics, and immunogenicity of repeated subcutaneous doses of anti-spike (S) SARS-CoV-2 monoclonal antibodies (REGN10933+REGN10987) in adult volunteers as related to COVID-19, https://clinicaltrials.gov/ct2/show/study/NCT04519437?term=Regeneron+Pharmaceuticals&amp;cond=%22Coronavirus+Infections%22&amp;draw=2&amp;rank=2#wrapper (accessed 20 October 2020).","References":[]},{"title2":"Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory adult patients with COVID-19, https://clinicaltrials.gov/ct2/show/NCT04425629?term=Regeneron+Pharmaceuticals&amp;cond=%22Coronavirus+Infections%22&amp;draw=2&amp;rank=3 (accessed 20 October 2020).","References":[]},{"title2":"Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for hospitalized adult patients with COVID-19, https://clinicaltrials.gov/ct2/show/NCT04426695?term=Regeneron+Pharmaceuticals&amp;cond=%22Coronavirus+Infections%22&amp;draw=2&amp;rank=4 (accessed 20 October 2020).","References":[]},{"title2":"Neutralization of virus infectivity by antibodies: old problems in new perspectives","References":[{"title3":"Accelerating next-generation vaccine development for global disease prevention"},{"title3":"Priorities for CMV vaccine development"},{"title3":"Immunologic correlates of protection induced by vaccination"},{"title3":"Correlates of vaccine-induced immunity"},{"title3":"Correlates of protection induced by vaccination"},{"title3":"Complex correlates of protection after vaccination"},{"title3":"Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses"},{"title3":"Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines"},{"title3":"Duration of humoral immunity to common viral and vaccine antigens"},{"title3":"Humoral immunity due to long-lived plasma cells"},{"title3":"Duration of antiviral immunity after smallpox vaccination"},{"title3":"How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?"},{"title3":"Antibodies in HIV-1 vaccine development and therapy"},{"title3":"HIV-1 vaccine development after STEP"},{"title3":"Dimensions of antigen recognition and levels of immunological specificity"},{"title3":"Molecular biological constraints on ligand-binding affinity and specificity"},{"title3":"Cohen's conjecture, Howard's hypothesis, and Ptashnes ptruth: an exploration of the relationship between affinity and specificity"},{"title3":"HIV vaccine design: insights from live attenuated SIV vaccines"},{"title3":"Prospects for live attenuated HIV"},{"title3":"Protective immunity induced by live attenuated simian immunodeficiency virus"},{"title3":"Medical virology of hepatitis B: how it began and where we are now"},{"title3":"Virus-like particles for the prevention of human papillomavirus-associated malignancies"},{"title3":"Why HIV virions have low numbers of envelope spikes: implications for vaccine development"},{"title3":"HIV vaccine design and the neutralizing antibody problem"},{"title3":"Immunecorrelates analysis of an HIV-1 vaccine efficacy trial"},{"title3":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand"},{"title3":"New paradigms for functional HIV-specific nonneutralizing antibodies"},{"title3":"Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts"},{"title3":"Neutralization of animal viruses"},{"title3":"Occupancy and mechanism in antibody-mediated neutralization of animal viruses"},{"title3":"Natural and man-made Vgene repertoires for antibody discovery"},{"title3":"Nanobodies: natural single-domain antibodies"},{"title3":"Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates"},{"title3":"Two distinct binding affinities of poliovirus for its cellular receptor"},{"title3":"Critical determinants of human alpha-defensin 5 activity against non-enveloped viruses"},{"title3":"Antiviral mechanisms of human defensins"},{"title3":"Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination"},{"title3":"Crystal structure of human enterovirus 71"},{"title3":"Structure of human enterovirus 71 in complex with a capsid-binding inhibitor"},{"title3":"Picornavirus-receptor interactions"},{"title3":"Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops"},{"title3":"Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120"},{"title3":"Plugging gp120s Cavity"},{"title3":"Termodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120"},{"title3":"Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4"},{"title3":"A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding"},{"title3":"Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G"},{"title3":"Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins"},{"title3":"Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus"},{"title3":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo"},{"title3":"HIV-1 virological synapse: live imaging of transmission"},{"title3":"Dangerous liaisons at the virological synapse"},{"title3":"Cell-to-cell spread of retroviruses"},{"title3":"Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies"},{"title3":"Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission"},{"title3":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies"},{"title3":"Neutralization of animal viruses"},{"title3":"Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism"},{"title3":"Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus"},{"title3":"The role of the complement system in virus infections"},{"title3":"Fc-glycosylation influences Fcgamma receptor binding and cell-mediated antihivactivity of monoclonal antibody 2G12"},{"title3":"Fc receptor but not complement binding is important in antibody protection against HIV"},{"title3":"A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fcgammariiia-Mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques"},{"title3":"Picornavirus entry"},{"title3":"Paramyxovirus entry"},{"title3":"Reovirus receptors, cell entry, and proapoptotic signaling"},{"title3":"Entry of influenza A virus: host factors and antiviral targets"},{"title3":"Attachment factors"},{"title3":"Mechanisms of enveloped virus entry into animal cells"},{"title3":"Entry of herpesviruses into cells: the enigma variations"},{"title3":"Cellular entry of retroviruses"},{"title3":"The ins and outs of hepatitis C virus entry and assembly"},{"title3":"Unrelated animal viruses share receptors"},{"title3":"Adenovirus:an eternal archetype"},{"title3":"The Coxsackie-Adenovirus Receptor: a new receptor in the immunoglobulin family involved in cell adhesion"},{"title3":"Entry of rhabdoviruses into animal cells"},{"title3":"Filovirus entry"},{"title3":"Entry of influenza virus"},{"title3":"Uncoating of non-enveloped viruses"},{"title3":"Flaviviruses: braking the entering"},{"title3":"Envelope protein dynamics in paramyxovirus entry"},{"title3":"Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm"},{"title3":"The molecular basis of HIV entry"},{"title3":"HIV entry: a game of hide-and-fuse?"},{"title3":"Virus entry: open sesame"},{"title3":"SFV infection in CHO cells: cell-type specific restrictions to productive virus entry at the cell surface"},{"title3":"Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody"},{"title3":"How antibodies block HIV infection: paths to an AIDS vaccine"},{"title3":"Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody"},{"title3":"Imaging poliovirus entry in live cells"},{"title3":"Capsid protein VP4 of human rhinovirus induces membrane permeability by the formation of a size-selective multimeric pore"},{"title3":"Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies"},{"title3":"Characterization of type 1 poliovirus by electrophoretic analysis"},{"title3":"An analysis of the physical and chemical factors involved in the reactivation of neutralized poliovirus by the method of freezing and thawing"},{"title3":"Neutralization of poliovirus: a hypothesis to explain the mechanism and the one hit character of the neutralization reaction"},{"title3":"Postadsorption neutralization of poliovirus"},{"title3":"Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion"},{"title3":"A model for neutralization of viruses based on antibody coating of the virion surface"},{"title3":"Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity"},{"title3":"Antibody neutralization of HIV-1"},{"title3":"Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation"},{"title3":"A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies"},{"title3":"The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope"},{"title3":"Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody"},{"title3":"Quantitative model of antibody-and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type"},{"title3":"Mathematical models: a key to understanding HIV envelope interactions?"},{"title3":"Estimating the stoichiometry of HIV neutralization"},{"title3":"Restricted occupancy models for neutralization of HIV virions and populations"},{"title3":"Estimating the stoichiometry of human immunodeficiency virus entry"},{"title3":"Stoichiometry of antibody neutralization of human immunodeficiency virus type 1"},{"title3":"Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1"},{"title3":"Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells"},{"title3":"Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1"},{"title3":"Studies with avian influenza A viruses: serological relations of the haemagglutinin and neuraminidase antigens of ten virus isolates"},{"title3":"Sensitization of influenza virus A2-Singapore by antineuraminidase"},{"title3":"Monoclonal anti-bodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing"},{"title3":"Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization"},{"title3":"Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines"},{"title3":"Complementmediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to siv challenge in the macaque model for HIV/AIDS"},{"title3":"Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization"},{"title3":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody"},{"title3":"Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization"},{"title3":"Kinetic dependence to HIV-1 entry inhibition"},{"title3":"Antibody interactions with rhinovirus: Lessons for mechanisms of neutralization and the role of immunity in viral evolution"},{"title3":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans"},{"title3":"Kinetic studies on the neutralization reaction between Japanese encephalitis virus and antiserum"},{"title3":"Antigenic determinants of influenza virus hemagglutinin VIII. Topography of the antigenic regions of influenza virus hemagglutinin determined by competitive radioimmunoassay with monoclonal antibodies"},{"title3":"DC-SIGN and DC-SIGNR interact with the glycoprotein of marburg virus and the S protein of severe acute respiratory syndrome coronavirus"},{"title3":"Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity"},{"title3":"Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies"},{"title3":"Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation"},{"title3":"MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1"},{"title3":"An immune-selected point mutation in the transmembrane protein of n immunodeficiency virus type 1 (HXB2-Env:Ala 582(  Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site"},{"title3":"Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change"},{"title3":"A new mechanism for the neutralization of enveloped viruses by antiviral antibody"},{"title3":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes"},{"title3":"Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited"},{"title3":"Neutralization of animal virus infectivity by antibody"},{"title3":"TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved"},{"title3":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)"},{"title3":"Intracellular antibody-mediated immunity and the role of TRIM21"},{"title3":"Regulation of virus neutralization and the persistent fraction by TRIM21"},{"title3":"Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody"},{"title3":"Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1"},{"title3":"Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-GAG antibody with prognosis"},{"title3":"Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1"},{"title3":"Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells"},{"title3":"Antibody-mediated neutralization of flaviviruses: a reductionist view"},{"title3":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development"},{"title3":"The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection"},{"title3":"Immune enhancement of viral infection"},{"title3":"Immunological enhancement of dengue virus replication"},{"title3":"Dengue viruses and mononuclear phagocytes, I: infection enhancement by non-neutralizing antibody"},{"title3":"Enhancement of dengue virus infection in monocytes by flavivirus antisera"},{"title3":"A study of the basic aspects of neutralization of two animal viruses, Western equine encephalitis virus and poliomyelitis virus"},{"title3":"Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies"},{"title3":"Quantitative relationships between an influenza virus and neutralizing antibody"},{"title3":"Structure of the recombinant alphavirus western equine encephalitis virus revealed by cryoelectron microscopy"},{"title3":"Observations on anti-phage sera. I: &quot;The percentage law&quot;"},{"title3":"A multi-hit model for the neutralization of animal viruses"},{"title3":"Methods for the detection and analysis of protein-protein interactions"},{"title3":"Overview of Biacore systems and their applications"},{"title3":"Surface plasmon resonance mass spectrometry: recent progress and outlooks"},{"title3":"Surface plasmon resonance biosensing"},{"title3":"Spying on HIV with SPR"},{"title3":"Whispering-gallery-mode biosensing: label-free detection down to single molecules"},{"title3":"GP120: target for neutralizing HIV-1 antibodies"},{"title3":"Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities"},{"title3":"Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein"},{"title3":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120"},{"title3":"A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers"},{"title3":"Highly stable trimers formed by human immunodefciency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin"},{"title3":"Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers"},{"title3":"Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9"},{"title3":"A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure"},{"title3":"Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1"},{"title3":"Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins"},{"title3":"A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120"},{"title3":"Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1"},{"title3":"Crystal structure of a soluble cleaved HIV-1 envelope trimer"},{"title3":"Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer"},{"title3":"Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits"},{"title3":"Mechanisms of virus neutralization by antibody"},{"title3":"Few and far between: how HIV may be evading antibody avidity"},{"title3":"Affinity, complementarity, cooperativity, and specificity in antibody recognition"},{"title3":"Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism"},{"title3":"Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity"},{"title3":"A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells"},{"title3":"Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity"},{"title3":"Modulation of Env content in virions of simian immunodeficiency virus: Correlation with cell surface expression and virion infectivity"},{"title3":"Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains"},{"title3":"Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature"},{"title3":"Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry"},{"title3":"Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10"},{"title3":"Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1"},{"title3":"Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus"},{"title3":"Dissociation of gp120 from HIV-1 virions induced by soluble CD4"},{"title3":"Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus"},{"title3":"The neutralization of arboviruses, II: neutralization in heterologous virus-serum mixtures with four group B arboviruses"},{"title3":"Antibodies to West Nile virus: a double-edged sword"},{"title3":"Dominant-negative effect of heterooligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex"},{"title3":"Observations on anti-phage sera. II: properties of incompletely neutralized phage"},{"title3":"Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms"},{"title3":"Neutralization of infectivity"},{"title3":"Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry"},{"title3":"Blocking of human immunodeficiency virus infection depends on cell density and viral stock age"},{"title3":"Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry"},{"title3":"Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion"},{"title3":"Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition"},{"title3":"The immunological reactions of the filterable viruses"},{"title3":"Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutininneuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization"},{"title3":"Selection of unique antigenic variants of Newcastle disease virus with neutralizing monoclonal antibodies and anti-immunoglobulin"},{"title3":"Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1"},{"title3":"The effect of divalent and univalent binding on antibody titration curves in solid-phase ELISA"},{"title3":"Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies"},{"title3":"Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors"},{"title3":"What is synergy?"},{"title3":"The combinations of haemoglobin with oxygen and with carbon monoxide. I"},{"title3":"The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications"},{"title3":"The Hill equation revisited: uses and misuses"},{"title3":"The search for synergy: a critical review from a response surface perspective"}]},{"title2":"Neutralizing antibodies for the treatment of COVID-19","References":[]},{"title2":"Carrillo, J. et al. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem. Biophys. Res. Commun. 10.1016/j.bbrc.2020.10.108 (2020).","References":[]},{"title2":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","References":[{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia."},{"title3":". Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2016 Jun 26]. http://www.who.int/emergencies/mers-cov/en/"},{"title3":"Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015."},{"title3":". Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients. V3.0 [cited 2016 Apr 29]. http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459835/merscov_for_clinicians_sept2015.pdf"},{"title3":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection."},{"title3":"SARS: systematic review of treatment effects."},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection."},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong."},{"title3":"Successful treatment of avian influenza with convalescent plasma."},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis."},{"title3":"Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection."},{"title3":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol."},{"title3":". CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2015 Sep 22]. http://www.cdc.gov/coronavirus/MERS/lab/lab-testing.html"},{"title3":"Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo."},{"title3":". Guidelines on assessing donor suitability for blood donation [cited 2015 Sep 22]. http://apps.who.int/iris/bitstream/10665/76724/1/9789241548519_eng.pdf?ua=1"},{"title3":". Position paper on collection and use of convalescent plasma or serum as an element in Middle East respiratory syndrome coronavirus response [cited 2015 Sep 22]. http://www.who.int/bloodproducts/brn/BRN_PositionPaperConvPlasmaMERSCoV_March2014.pdf"},{"title3":"Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction."},{"title3":"Transmission of MERS-coronavirus in household contacts."},{"title3":"Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study."},{"title3":"The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies."},{"title3":"MERS coronaviruses in dromedary camels, Egypt."},{"title3":"Lack of MERS coronavirus neutralizing antibodies in humans, Eastern Province, Saudi Arabia."},{"title3":"Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012."},{"title3":"Disappearance of antibodies to SARS-associated coronavirus after recovery."},{"title3":"Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge."},{"title3":"The time course of the immune response to experimental coronavirus infection of man."},{"title3":"Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia."},{"title3":". South Korea tries old weapon to fight MERS [cited 2015 Sep 22]. http://www.wsj.com/articles/south-korea-tries-old-weapon-to-fight-mers-1434451587"},{"title3":"Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection."}]},{"title2":"Use of convalescent plasma therapy in SARS patients in Hong Kong","References":[{"title3":"A novel coronavirus-associated severe acute respiratory syndrome"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Bolivian hemorrhagic fever. A report of four cases"},{"title3":"Treatment of Argentine hemorrhagic fever with convalescent's plasma 4433 cases [in French]"},{"title3":"The use of Lassa fever convalescent plasma in Nigeria"},{"title3":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee"},{"title3":"Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treatment of West Nile virus infection in mice"},{"title3":"West Nile encephalitis"},{"title3":"Update: severe acute respiratory syndrome"},{"title3":"Prospective study of the clinical progression and viral load of SARS-associated coronavirus pneumonia in a community outbreak"}]},{"title2":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","References":[]},{"title2":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","References":[{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV):update (26 May 2014)"},{"title3":"Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do"},{"title3":"Treatment of MERS-CoV: decision support tool v.1.0"},{"title3":"State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans"},{"title3":"Hyperimmune iv immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a(H1N1) infection"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"SARS: systematic review of treatment effects"},{"title3":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital"},{"title3":"The management of coronavirus infections with particular reference to SARS"},{"title3":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement"},{"title3":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the effectiveness of convalescent plasma for the treatment of severe acute respiratory infections of viral aetiology: a systematic review. PROSPERO 2013CRD42013005091"},{"title3":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011"},{"title3":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses"},{"title3":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective"},{"title3":"Use of serum in the treatment of influenza-pneumonia"},{"title3":"Treatment of influenza with injections of blood from convalescents"},{"title3":"Treatment of influenza pneumonia with serum from convalescents"},{"title3":"Treatment of influenza pneumonia by use of convalescent human serum"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Clinical research during a public health emergency: a systematic review of severe pandemic influenza management"},{"title3":"Successful treatment of avian influenza with convalescent plasma"},{"title3":"Convalescent plasma for prophylaxis and treatment of severe pandemic influenza A (H1N1) 2009 infection: Case reports"},{"title3":"Treatment of severe acute respiratory syndrome with convalescent plasma"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula"},{"title3":"Letter to the editor"},{"title3":"Treatment of severe acute respiratory syndrome with convalescent plasma, author reply"},{"title3":"Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area"},{"title3":"Treatment of influenzal pneumonia with plasma of convalescent patients"},{"title3":"Treatment of influenzal pneumonia by the use of convalescent human serum"},{"title3":"Human serum in influenza"},{"title3":"Clinical characteristics of 26 human cases of highly pathogenic avian 36]influenza A (H5N1) virus infection in China"},{"title3":"Retrospective study on collecting convalescent donors's plasma in treatment of patients with pandemic influenza A (H1N1) virus infection"},{"title3":"Human serum in the treatment of influenza bronchopneumonia"},{"title3":"Convalescent serum in treatment of influenza"},{"title3":"Convalescent serum in the prevention and treatment of influenza"},{"title3":"Plasma therapy in influenza"},{"title3":"Report of influenza treated with serum from recovered cases"},{"title3":"Convalescent serum in the treatment of influenza pneumonia"},{"title3":"The use of the serum of convalescents in the treatment of influenza pneumonia: A summary of the results in a series of one hundred and one cases"},{"title3":"Advances in clinical diagnosis and treatment of severe acute respiratory syndrome"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Serum treatment of postinfluenzal bronchopneumonia"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Treatment of Severe Pandemic Influenza A/H1N1 Infection"},{"title3":"Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?"}]},{"title2":"Haagmans, B. L. et al. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. Preprint at bioRxiv10.1101/2020.08.24.264630 (2020).","References":[]},{"title2":"Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis","References":[]},{"title2":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","References":[]},{"title2":"Joyner, M. J. et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. Preprint at medRxivhttps://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1 (2020).","References":[]},{"title2":"Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA324, 1-11 (2020).","References":[]},{"title2":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","References":[]},{"title2":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","References":[{"title3":"Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China [published online ahead of print February 28, 2020]. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [published online ahead of print March 18, 2020]. N Engl J Med. https://doi.org/10.1056/NEJMe2005477."},{"title3":"Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19 [published online ahead of print February 27, 2020]. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30141-9."},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"Zunyou W, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print February 24, 2020]. JAMA.https://doi.org/10.1001/jama.2020.2648."},{"title3":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published online ahead of print March 11, 2020]. Lancet. https://doi.org/10.1016/S0140-6736(20)30566-3."},{"title3":"Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China [published online ahead of print March 12, 2020]. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa248."},{"title3":"Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases [published online ahead of print March 20, 2020]. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(20)30121-1."},{"title3":"Surviving sepsis guidelines: a continuous move toward better care of patients with sepsis"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Specificity, kinetics and longevity of antibody responses to avian influenza A (H7N9) virus infection in humans"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques [published online ahead of print March 13, 2020]. bioRxiv. https://doi.org/10.1101/2020.03.13.990226."}]},{"title2":"COVID-19 expanded access program, https://www.uscovidplasma.org/ (accessed 29 July 2020).","References":[]},{"title2":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","References":[{"title3":"Remdesivir for the treatment of COVID-19-final report"},{"title3":"Dexamethasone in hospitalized patients with COVID-19"},{"title3":"Repurposed antiviral drugs for COVID-19:interim WHO solidarity trial results"},{"title3":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review"},{"title3":"COVID-19 illness in native and immuno-suppressed states: a clinical-therapeutic staging proposal"},{"title3":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread"},{"title3":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial"},{"title3":"Ivermectin: panacea for resource-poor communities?"},{"title3":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses"},{"title3":"Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia"},{"title3":"Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature"},{"title3":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study"},{"title3":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality"},{"title3":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern Anatolia"},{"title3":"Treatment for emerging viruses: convalescent plasma and COVID-19"},{"title3":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital"},{"title3":"Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)"},{"title3":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia"},{"title3":"Dexamethasone in hospitalized patients with COVID-19"},{"title3":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis"},{"title3":"Convalescent plasma antibody levels and the risk of death from COVID-19"},{"title3":"Early high-titer plasma therapy to prevent severe COVID-19 in older adults"},{"title3":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients"},{"title3":"Viral clearance after early corticosteroid treatment in patients with moderate or severe COVID-19"}]},{"title2":"Joyner, M. J. et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J. Clin. Invest.130, 4791-4797 (2020).","References":[]},{"title2":"Convalescent plasma treatment of severe COVID-19: a matched control study","References":[{"title3":"Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"The 2020 race towards SARS-CoV-2 specific vaccines"},{"title3":"SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy"},{"title3":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"},{"title3":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention"},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study"},{"title3":"Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State"},{"title3":"Acute pulmonary embolism and COVID-19 pneumonia: A random association?"},{"title3":"Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19"},{"title3":"Remdesivir for the Treatment of Covid-19-Preliminary Report. Reply"},{"title3":"Dexamethasone in Hospitalized Patients with Covid-19"},{"title3":"Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial"},{"title3":"The Emerging Role of Convalescent Plasma in the Treatment of COVID-19"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Convalescent plasma in Covid-19: Possible mechanisms of action"},{"title3":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study"},{"title3":"Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial)"},{"title3":"Convalescent plasma therapy in patients with COVID-19"},{"title3":"Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Convalescent Plasma for COVID-19. A randomized clinical trial"},{"title3":"Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience"},{"title3":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial"},{"title3":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults"},{"title3":"Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study"},{"title3":"Clinical Memorandum: EUA 26382: Emergency Use Authorization (EUA) Request (Original Request 8/12/20; Amended Request 8/23/20)"},{"title3":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq"},{"title3":"Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality"},{"title3":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma"},{"title3":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia"},{"title3":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China"},{"title3":"Early mortality benefit with COVID-19 convalescent plasma: A matched control study"},{"title3":"Effectiveness of convalescent plasma in Indian patients with COVID-19"},{"title3":"Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome"},{"title3":"Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients:propensity-score matched case-control study"},{"title3":"Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia"},{"title3":"Safety and efficacy of convalescent plasma in elderly COVID-19 patients: The RESCUE trial"},{"title3":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial"},{"title3":"Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma"},{"title3":"Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study"},{"title3":"A matched cohort study of convalescent plasma therapy for COVID-19"},{"title3":"Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients"},{"title3":"FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID-19 Treatment, An-other Achievement in Administration's Fight Against Pandemic"},{"title3":"FDA In Brief: FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma to Reflect New Data"},{"title3":"Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study"},{"title3":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses"},{"title3":"The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation"},{"title3":"Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19"},{"title3":"Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19"},{"title3":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial"},{"title3":"Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report"},{"title3":"Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients"},{"title3":"Antibody-dependent enhancement of severe dengue disease in humans"},{"title3":"Viral-Induced Enhanced Disease Illness"},{"title3":"Fc receptors in antibody-dependent enhancement of viral infections"}]},{"title2":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial","References":[]},{"title2":"Pau, A. K. et al. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 treatment guidelines panel. Ann. Intern. Med.174, 93-95 (2020).","References":[]},{"title2":"U.S. Food and Drug Administration. Convalescent Plasma Letter of Authorization, August 2020, https://www.fda.gov/media/141477/download (accessed 6 September 2020).","References":[]},{"title2":"The Dutch National Institute for Public Health and Environment. COVID-19 Guideline (only available in Dutch), https://lci.rivm.nl/richtlijnen/covid-19 (accessed 5 October 2020, last updated 5 October 2020).","References":[]},{"title2":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). COVID-19 Report 19 May 2020, https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_19MAY20.pdf (accessed 27 May 2020).","References":[]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: challenges for global health governance"},{"title3":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses:a statement of the Coronavirus Study Group"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society"},{"title3":"KDIGO clinical practice guidelines for acute kidney injury"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Chinese management guideline for COVID-19 (version 6.0)"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Predictors of mortality in Middle East respiratory syndrome (MERS)"},{"title3":"Exacerbated innate host response to SARS-CoV in aged non-human primates"},{"title3":"The immunopathogenesis of sepsis in elderly patients"},{"title3":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"},{"title3":"Serial evaluation of the SOFA score to predict outcome in critically ill patients"},{"title3":"Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network"},{"title3":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study"},{"title3":"Acute pneumonia and the cardiovascular system"},{"title3":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis"},{"title3":"Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"D-dimer is a significant prognostic factor in patients with suspected infection and sepsis"},{"title3":"Risk of myocardial infarction and stroke after acute infection or vaccination"},{"title3":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality"},{"title3":"Cardiovascular complications of acute respiratory infections: current research and future directions"},{"title3":"Regulation of ACE2 in cardiac myocytes and fibroblasts"},{"title3":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase"},{"title3":"Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus infection"},{"title3":"Viral load kinetics of MERS coronavirus infection"},{"title3":"Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection"},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients"}]},{"title2":"The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects","References":[{"title3":"Coronavirus disease (COVID-19) outbreak"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study"},{"title3":"Task force COVID-19 form Infectious Disease Department and Informatics Department ISDS, National update: May 7, 2020. Available at: https://www.iss.it/en/comunicati-stampa1. Accessed May 7, 2020."},{"title3":"Update report of COVID-19 situation in Spain. Report COVID-19 number 9. May 7, 2020"},{"title3":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis"},{"title3":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study"},{"title3":"National COVID-19 weekly summary report: 7 May 2020"},{"title3":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area"},{"title3":"Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses"},{"title3":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials"},{"title3":"Coronavirus age, sex, demographics (COVID-19):Worldometer"},{"title3":"Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Coronavirus: The Geriatric Emergency of 2020. Joint Document of the Geriatric Cardiology Section of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology [In Spanish]"},{"title3":"The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: Insights from cardiovascular aging science"},{"title3":"Coronavirus disease 2019 (COVID-19) in Italy"}]},{"title2":"Gender differences in patients with COVID-19: focus on severity and mortality","References":[{"title3":"A novel coronavirus from patients with Pneumonia in China, 2019"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS"},{"title3":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes"},{"title3":"Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?"},{"title3":"Gender differences in patients with COVID-19: focus on severity and mortality"}]},{"title2":"C-reactive protein level may predict the risk of COVID-19 aggravation","References":[{"title3":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea"},{"title3":"2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: an uncommon radiological presentation"},{"title3":"Diagnosis and treatment of new coronavirus pneumonia (trial sixth edition)"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"C-reactive protein, inflammation, and innate immunity"},{"title3":"C-reactive protein: ligands, receptors and role in inflammation"},{"title3":"Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections"},{"title3":"Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia"},{"title3":"Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia"},{"title3":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore"}]},{"title2":"Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis","References":[{"title3":"World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)."},{"title3":"[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]."},{"title3":"A novel coronavirus outbreak of global health concern."},{"title3":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting wuhan."},{"title3":"Coronavirus disease (COVID-19) situation-reports."},{"title3":"Clinical characteristics of coronavirus disease 2019 in China."},{"title3":"Analysis of clinical characteristics of 223 patients with novel coronavirus pneumonia in Chongqing."},{"title3":"Clinical features of 153 patients with COVID-19 in Chongqing municipality."},{"title3":"Clinical features of coronavirus disease 2019 in Northeast area of Chongqing: analysis of 143 cases."},{"title3":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)."},{"title3":"[Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]."},{"title3":"[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]."},{"title3":"Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019."},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China."},{"title3":"Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019."},{"title3":"Clinical characteristics, treatment, and prognosis in 89 cases of COVID-2019."},{"title3":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients."},{"title3":"[Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia]."},{"title3":"Characteristics of COVID-19 infection in beijing."},{"title3":"Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage."},{"title3":"Epidemiological and clinical characteristics of 46 newly-admitted coronavirus disease 2019 cases in Beijing."},{"title3":"Clinical characteristics analysis of novel coronavirus pneumonia in Hunan province."},{"title3":"COVID-19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China."},{"title3":"Clinical characteristics and treatment strategies of 79 patients with COVID-19."},{"title3":"Analysis of clinical characteristics of 49 patients with Novel Coronavirus Pneumonia in Jiangxi province."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: a descriptive study."},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019."},{"title3":"Use Stones from Another Mountain to Polish One's Jade: Learn from MERS Studies toexplore potential mechanisms underlying the effect of diabetes mellitus on COVID-19."},{"title3":"Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov."},{"title3":"Two Things About COVID-19 Might Need Attention."},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in wuhan, China: a single-centered, retrospective, observational study."},{"title3":"Multiple organ infection and the pathogenesis of SARS."},{"title3":"Molecular mechanisms of coronavirus RNA capping and methylation."},{"title3":"Review of bats and SARS."},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding."},{"title3":"[An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)]."},{"title3":"Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19)."},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in wuhan, China: a descriptive study."},{"title3":"[Expression of the monoclonal antibody against nucleocapsid antigen of SARS-associated coronavirus in autopsy tissues from SARS patients]."},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection."},{"title3":"Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - united states, february 12-march 28, 2020."},{"title3":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy."},{"title3":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement."},{"title3":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group."},{"title3":"Chinese Journal of Infection Control."},{"title3":"The case of the misleading funnel plot."}]},{"title2":"Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis","References":[{"title3":"From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:343-6."},{"title3":"The SARS-CoV-2 outbreak: What we know"},{"title3":"The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis"},{"title3":"Coronavirus disease 2019: What we know?"},{"title3":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients"},{"title3":"Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis"},{"title3":"Clinical features and treatment analysis of 79 Coronovirus infected pneumonia"},{"title3":"Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19"},{"title3":"Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease"},{"title3":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury"},{"title3":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Retrospective study on the epidemiological characteristics of 139 patients with novel coronavirus pneumonia on the effects of Severity"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area"},{"title3":"Hematological findings in SARS patients and possible mechanisms (review)"},{"title3":"Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets"},{"title3":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients"},{"title3":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients"},{"title3":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?"},{"title3":"Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV"},{"title3":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study"}]},{"title2":"An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment","References":[{"title3":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period"},{"title3":"Long Q. X., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845-848 (2020)."},{"title3":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients"},{"title3":"Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward"},{"title3":"Zhao J., et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. pii: ciaa344, (2020). [Epub ahead of print]."},{"title3":"MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015"},{"title3":"Slot E., et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Nature Res.https://www.researchsquare.com/article/rs-25862/v1 (2020)."},{"title3":"Lassauniere R., et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. 10.1101/2020.04.09.20056325v1 (2020)."}]},{"title2":"Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study"},{"title3":"Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic"},{"title3":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature10.1038/s41586-020-2196-x (2020)."},{"title3":"Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients"},{"title3":"Lan, L. et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA10.1001/jama.2020.2783 (2020)."},{"title3":"CDC. Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance).https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html (2020)."},{"title3":"ECDC. Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19:first update 8 April 2020. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidance-discharge-and-ending-isolation-first%20update.pdf (2020)"},{"title3":"WHO. Clinical management of COVID-19. WHO Reference Number: WHO/2019-nCoV/clinical/2020.5. https://www.who.int/publications/i/item/clinical-management-of-covid-19 (2020)."},{"title3":"Prolonged virus shedding even after seroconversion in a patient with COVID-19"},{"title3":"Predicting infectious SARS-CoV-2 from diagnostic samples"},{"title3":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature10.1038/s41586-020-2342-5 (2020)."},{"title3":"A novel coronavirus emerging in China:key questions for impact assessment"},{"title3":"Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA10.1001/jama.2020.3786 (2020)."},{"title3":"Viral dynamics in mild and severe cases of COVID-19"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19"},{"title3":"Temporal dynamics in viral shedding and transmissibility of COVID-19"},{"title3":"Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19"},{"title3":"CDC. Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19:Decision Memo. https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html (2020)."},{"title3":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients"},{"title3":"An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS)"},{"title3":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR"},{"title3":"Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract"},{"title3":"Statistical analysis of correlated data using generalized estimating equations: an orientation"},{"title3":"The R package geepack for generalized estimating equations"}]},{"title2":"Virological assessment of hospitalized patients with COVID-2019","References":[]},{"title2":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","References":[]},{"title2":"Passive immunity in the prevention of rabies","References":[]},{"title2":"Prevention of hepatitis B virus infection: from the past to the future","References":[]},{"title2":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis.26, 1478-1488 (2020).","References":[]},{"title2":"Wang, X. et al. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clin. Infect. Dis. ciaa721 (2020).","References":[]},{"title2":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 : preliminary report. N. Engl. J. Med. 384, 693-704 (2020).","References":[]},{"title2":"An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment","References":[{"title3":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period"},{"title3":"Long Q. X., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845-848 (2020)."},{"title3":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients"},{"title3":"Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward"},{"title3":"Zhao J., et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. pii: ciaa344, (2020). [Epub ahead of print]."},{"title3":"MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015"},{"title3":"Slot E., et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Nature Res.https://www.researchsquare.com/article/rs-25862/v1 (2020)."},{"title3":"Lassauniere R., et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. 10.1101/2020.04.09.20056325v1 (2020)."}]},{"title2":"Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med.10.1038/s41591-020-0965-6 (2020).","References":[]},{"title2":"Petkova, E., Antman, E. M. &amp; Troxel, A. B. Pooling data from individual clinical trials in the COVID-19 era. JAMA, 10.1001/jama.2020.13042 (2020).","References":[]},{"title2":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science369, 643-650 (2020).","References":[]},{"title2":"A human monoclonal antibody blocking SARS-CoV-2 infection","References":[]},{"title2":"University of Oxford. RECOVERY Trial, https://www.recoverytrial.net/ (accessed 31 July 2020).","References":[]},{"title2":"REMAP-CAP, https://www.remapcap.org/ (accessed 31 July 2020).","References":[]},{"title2":"Convalescent plasma antibody levels and the risk of death from Covid-19","References":[{"title3":"Hark back: passive immunotherapy for influenza and other serious infections."},{"title3":"Serum therapy revisited: animal models of infection and development of passive antibody therapy."},{"title3":"Return to the past: the case for antibody-based therapies in infectious diseases."},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review."},{"title3":"Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy."},{"title3":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial."},{"title3":"Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma."},{"title3":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq."},{"title3":"Convalescent plasma for COVID-19: a multicenter, randomized clinical trial."},{"title3":"Convalescent plasma for COVID-19: a randomized clinical trial."},{"title3":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)."},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients."},{"title3":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma: a proof of concept single arm multicenter trial."},{"title3":"Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report."},{"title3":"Use of convalescent plasma in hospitalized patients with COVID-19: case series."},{"title3":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019."},{"title3":"Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study."},{"title3":"Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia."},{"title3":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion."},{"title3":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study."},{"title3":"Convalescent plasma for patients with severe COVID-19: a matched cohort study."},{"title3":"Convalescent plasma therapy in patients with COVID-19."},{"title3":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients."},{"title3":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients."},{"title3":"Deployment of convalescent plasma for the prevention and treatment of COVID-19."},{"title3":"Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2."},{"title3":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization."},{"title3":"Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients."},{"title3":"The REDCap consortium: building an international community of software platform partners."},{"title3":"Research electronic data capture (REDCap) : a metadata-driven methodology and workflow process for providing translational research informatics support."},{"title3":"Remdesivir for the treatment of Covid-19 : final report."},{"title3":"Effect of hydroxychloroquine in hospitalized patients with Covid-19."},{"title3":"Dexamethasone in hospitalized patients with Covid-19 : preliminary report."},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial."},{"title3":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial."},{"title3":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality."},{"title3":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study."},{"title3":"Modernising epidemic science: enabling patient-centred research during epidemics."}]},{"title2":"Convalescent plasma to limit SARS-CoV-2 associated complications, https://clinicaltrials.gov/ct2/show/NCT04373460?term=sullivan&amp;cond=covid&amp;draw=2&amp;rank=1 (accessed 31 July 2020).","References":[]},{"title2":"World Health Organizatin. Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis, https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis (2020).","References":[]},{"title2":"The Dutch General Practicioner Association. Flu Vaccination: General Practicioner Guideline (only available in Dutch), https://www.nhg.org/sites/default/files/content/nhg_org/uploads/final_griep_sep_2020.pdf (accessed 19 October 2020).","References":[]},{"title2":"A proportional hazards model for the subdistribution of a competing risk","References":[]}]},{"title1":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","References":[{"title2":"SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy","References":[]},{"title2":"Convalescent plasma in Covid-19: Possible mechanisms of action","References":[{"title3":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"},{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Pathogenicity of turkey coronavirus in turkeys and chickens"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding"},{"title3":"Advances in clinical diagnosis and treatment of severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning"},{"title3":"On the molecular determinants and the mechanism of the SARS-CoV-2 attack 2020"},{"title3":"Molecular mimicry and autoimmunity"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19"},{"title3":"Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial"},{"title3":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial"},{"title3":"Convalescent plasma: New evidence for an old therapeutic tool?"},{"title3":"Ebola virus convalescent blood products: Where we are now and where we may need to go"},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis"},{"title3":"Ebola virus disease: An emerging and re-emerging viral threat"},{"title3":"West Nile virus neutralization by US plasma-derived immunoglobulin products"},{"title3":"The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis"},{"title3":"Treatment of West Nile virus encephalitis with intravenous immunoglobulin"},{"title3":"Evaluation of convalescent plasma for Ebola virus disease in Guinea"},{"title3":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow"},{"title3":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy"},{"title3":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease"},{"title3":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)"},{"title3":"Immunotherapy in clinical medicine: Historical perspective and current status"},{"title3":"Mechanisms of immunotherapy: A historical perspective"},{"title3":"IVIG in autoimmunity and cancer--efficacy versus safety"},{"title3":"Safety of intravenous immunoglobulin (IVIG) therapy"},{"title3":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea"},{"title3":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience"},{"title3":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China"},{"title3":"Treatment of 5 critically ill patients with Covid-19 with convalescent plasma"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital"},{"title3":"Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area"},{"title3":"Letter to editor"},{"title3":"Treatment of severe acute respiratory syndrome with convalescent plasma"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)"},{"title3":"Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China"},{"title3":"Successful treatment of avian influenza with convalescent plasma"},{"title3":"The management of coronavirus infections with particular reference to SARS"},{"title3":"Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula"},{"title3":"Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how"},{"title3":"Ethics and blood donation: A marriage of convenience"},{"title3":"Deployment of convalescent plasma for the prevention and treatment of COVID-19"},{"title3":"Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016"},{"title3":"Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan"},{"title3":"Treatment of platelet concentrates and plasma with riboflavin and UV light: Impact in bacterial reduction"},{"title3":"Plasma components: Properties, differences, and uses"},{"title3":"The spike protein of SARS-CoV--a target for vaccine and therapeutic development"},{"title3":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody"},{"title3":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications"},{"title3":"Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus"},{"title3":"Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses"},{"title3":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS"},{"title3":"Mechanisms of action of intravenous immunoglobulin"},{"title3":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19"},{"title3":"Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation"},{"title3":"F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins"},{"title3":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis"},{"title3":"Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy"},{"title3":"Original antigenic sin: A comprehensive review"},{"title3":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins"},{"title3":"The convalescent sera option for containing COVID-19"},{"title3":"Anti-inflammatory actions of intravenous immunoglobulin"},{"title3":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study"},{"title3":"Influence of FCRN expression on lung decline and intravenous immunoglobulin catabolism in common variable immunodeficiency patients"},{"title3":"The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"},{"title3":"Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia"},{"title3":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor"},{"title3":"FcgammaRIIb expression on B cells is associated with treatment efficacy for acute rejection after kidney transplantation"},{"title3":"Role of activating FcgammaR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response"},{"title3":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"},{"title3":"Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin"},{"title3":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin"},{"title3":"Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients"},{"title3":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production"},{"title3":"Therapeutic normal IgG intravenous immunoglobulin activates Wnt-beta-catenin pathway in dendritic cells"},{"title3":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus"},{"title3":"Interferon-alpha inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: Comment on the article by Wiedeman et al"},{"title3":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation"},{"title3":"Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells"},{"title3":"Effect of intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL)"},{"title3":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection"},{"title3":"Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP"},{"title3":"Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells"},{"title3":"Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease"},{"title3":"Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin"},{"title3":"Comparison of different IVIg preparations on IL-17 production by human Th17 cells"},{"title3":"Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss"},{"title3":"Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy"},{"title3":"Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc gamma IIB receptor on B cells"},{"title3":"TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase"},{"title3":"BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer"},{"title3":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway"},{"title3":"Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)"},{"title3":"IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes"},{"title3":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19"},{"title3":"Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state"},{"title3":"High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats"},{"title3":"Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection"},{"title3":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review"}]},{"title2":"Hark back: passive immunotherapy for influenza and other serious infections","References":[]},{"title2":"Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea","References":[{"title3":"Ebola situation report : September 9, 2015"},{"title3":"Clinical illness and outcomes in patients with Ebola in Sierra Leone"},{"title3":"Clinical presentation of patients with Ebola virus disease in Conakry, Guinea"},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis"},{"title3":"Passive antibody therapy for infectious diseases"},{"title3":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients"},{"title3":"Randomised controlled trials for Ebola: practical and ethical issues"},{"title3":"Filovirus haemorrhagic fever guideline"},{"title3":"Ebola virus disease among children in West Africa"},{"title3":"Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea"},{"title3":"Computing adjusted risk ratios and risk differences in Stata"},{"title3":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp"},{"title3":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease"},{"title3":"Ebola hemorrhagic fever and pregnancy"},{"title3":"Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain"}]},{"title2":"Use of convalescent plasma therapy in SARS patients in Hong Kong","References":[{"title3":"A novel coronavirus-associated severe acute respiratory syndrome"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Bolivian hemorrhagic fever. A report of four cases"},{"title3":"Treatment of Argentine hemorrhagic fever with convalescent's plasma 4433 cases [in French]"},{"title3":"The use of Lassa fever convalescent plasma in Nigeria"},{"title3":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee"},{"title3":"Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treatment of West Nile virus infection in mice"},{"title3":"West Nile encephalitis"},{"title3":"Update: severe acute respiratory syndrome"},{"title3":"Prospective study of the clinical progression and viral load of SARS-associated coronavirus pneumonia in a community outbreak"}]},{"title2":"Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis","References":[]},{"title2":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","References":[{"title3":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection"},{"title3":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance"},{"title3":"Topaz-Denoise: gen- eral deep denoising models for cryoEM and cryoET"},{"title3":"Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs"},{"title3":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex"},{"title3":"Commonality despite exceptional diversity in the baseline human antibody repertoire"},{"title3":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability"},{"title3":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells"},{"title3":"Growth, detection, quantification, and inactivation of SARS-CoV-2"},{"title3":"Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2"},{"title3":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies"},{"title3":"Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells"},{"title3":"Structural basis for a convergent immune response against Ebola virus"},{"title3":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies"},{"title3":"A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes"},{"title3":"Longitudinal analysis of the human B cell response to Ebola virus infection"},{"title3":"Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak"},{"title3":"Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail"},{"title3":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV"},{"title3":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus"},{"title3":"Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics"},{"title3":"Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease"},{"title3":"Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition"},{"title3":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses"},{"title3":"Vaccine-induced antibodies that neutralize Group 1 and Group 2 influenza A viruses"},{"title3":"SARS-CoV-2 vaccines in development"},{"title3":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients"},{"title3":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike"},{"title3":"Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses"},{"title3":"Enhancing dengue virus maturation using a stable furin over-expressing cell line"},{"title3":"B cell clonal expansion and convergent antibody responses to SARS-CoV-2"},{"title3":"Negative staining and image classification - Powerful tools in modern electron microscopy"},{"title3":"Rapid development of broadly influenza neutralizing antibodies through redundant mutations"},{"title3":"UCSF Chimera-a visualization system for exploratory research and analysis"},{"title3":"Spike mutation D614G alters SARS-CoV-2 fitness"},{"title3":"cryo- SPARC: algorithms for rapid unsupervised cryo-EM structure determination"},{"title3":"Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class"},{"title3":"Deletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concern"},{"title3":"Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals"},{"title3":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model"},{"title3":"Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection"},{"title3":"Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual"},{"title3":"Persistence of circulating B memory cell clones with potential for dengue virus disease enhancement for decades following infec- tion"},{"title3":"High frequency of shared clonotypes in human B cell receptor repertoires"},{"title3":"PyIR: a scalable wrapper for processing billions of immunoglobulin and T cell receptor sequences using IgBLAST"},{"title3":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses"},{"title3":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein"},{"title3":"Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain"},{"title3":"Structural insights into coronavirus entry"},{"title3":"Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa"},{"title3":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms"},{"title3":"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma"},{"title3":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus"},{"title3":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7"},{"title3":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants"},{"title3":"Broad neutralization of SARS-related viruses by human monoclonal antibodies"},{"title3":"H5N1 vaccine-elicited memory B cells are genetically constrained by the IGHV locus in the recognition of a neutralizing epitope in the hemagglutinin stem"},{"title3":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma"},{"title3":"HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies"},{"title3":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function"},{"title3":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing"},{"title3":"A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody"},{"title3":"Structural basis of a shared antibody response to SARS-CoV-2"},{"title3":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV"},{"title3":"Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants"},{"title3":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes"},{"title3":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice"},{"title3":"Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors"},{"title3":"Potently neutralizing and protective human antibodies against SARS-CoV-2"},{"title3":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein"},{"title3":"Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface"}]},{"title2":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","References":[]},{"title2":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study","References":[{"title3":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia"},{"title3":"Deployment of convalescent plasma for the prevention and treatment of COVID-19"},{"title3":"Convalescent plasma in Covid-19: possible mechanisms of action"},{"title3":"Management of COVID-19 virus infection by convalescent plasma;"},{"title3":"Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic"},{"title3":"The convalescent sera option for containing COVID -19"},{"title3":"Convalescent plasma to treat COVID -19: possibilities and challenges"},{"title3":"COVID-19 convalescent plasma transfusion"},{"title3":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019"},{"title3":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea"},{"title3":"Recommendations for Investigational COVID-19 Convalescent Plasma https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma."},{"title3":"An EU programme of COVID-19 convalescent plasma collection and transfusion https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf."},{"title3":"Early safety indicators of COVID-19 convalescent plasma in 5,000 patients"},{"title3":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?"},{"title3":"Time course of lung changes on chest CT during recovery from 2019 novel Coronavirus (COVID-19) pneumonia"},{"title3":"Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study"},{"title3":"Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State"}]},{"title2":"Use of convalescent plasma in hospitalized patients with COVID-19: case series","References":[{"title3":"World Health Organization,. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 25 May 2020."},{"title3":"An interactive web-based dashboard to track COVID-19 in real time"},{"title3":"Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection [published online ahead of print 31 March 2020]. Chest. doi:10.1016/j.chest.2020.03.039."},{"title3":"Convalescent plasma to treat COVID-19: possibilities and challenges"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Joyner M, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients [published online ahead of print 11 June 2020]. J Clin Invest. doi:10.1101/2020.05.12.20099879."},{"title3":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins"},{"title3":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19"},{"title3":"Yin S, Huang M, Li D, Tang N,. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 [published online ahead of print 3 April 2020]. J Thromb Thrombolysis. doi:10.1007/s11239-020-02105-8."},{"title3":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19"},{"title3":"Covid-19 in critically ill patients in the Seattle region - case series"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state"},{"title3":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019"},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"},{"title3":"National Institutes of Health,. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. Available at: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. Accessed 29 April 2020."},{"title3":"Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members,. Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print 22 May 2020]. N Engl J Med. doi:10.1056/NEJMoa2007764."}]},{"title2":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion","References":[{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"World Health Organization,. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 9 June 2020."},{"title3":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)"},{"title3":"The convalescent sera option for containing COVID-19"},{"title3":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online ahead of print 15 April 2020]. J Med Virol. doi:10.1002/jmv.25882."},{"title3":"Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial [published online ahead of print 3 June 2020]. JAMA. doi:10.1001/jama.2020.10044."},{"title3":"COVID-19: immunopathology and its implications for therapy"},{"title3":"Deployment of convalescent plasma for the prevention and treatment of COVID-19"},{"title3":"Joyner M, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv. doi:10.1101/2020.05.12.20099879."},{"title3":"Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv. doi:10.1101/2020.05.20.20102236."},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Convalescent plasma for patients with COVID-19"}]},{"title2":"Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20 000 Hospitalized Patients. Mayo Clin Proc 2020 Jul 19; www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/ Accessed on 25 Aug 2020.","References":[]},{"title2":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","References":[]},{"title2":"Convalescent Plasma for COVID-19. A randomized clinical trial.","References":[{"title3":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome"},{"title3":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience"},{"title3":"Use of convalescent plasma therapy in SARS patients in Hong Kong"},{"title3":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Treatment of 5 critically ill patients with covid-19 with convalescent plasma"},{"title3":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients"},{"title3":"Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study"},{"title3":"Use of convalescent plasma in hospitalized patients with COVID-19: case series"},{"title3":"Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, et al. Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a matched control study. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality"},{"title3":"Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials"},{"title3":"Design, analysis and reporting of multi-arm trials and strategies to address multiple testing"},{"title3":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial"},{"title3":"Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;m3939."},{"title3":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia"},{"title3":"Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Infect Dis (except HIV/AIDS); 2020."},{"title3":"AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial"},{"title3":"Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Lahiri A, et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, de Molina RM, Torres F, et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. Infect Dis (except HIV/AIDS); 2020."},{"title3":"Early high-titer plasma therapy to prevent severe COVID-19 in older adults"},{"title3":"O'Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt CM, et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. Infect Dis (except HIV/AIDS); 2021."},{"title3":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial"},{"title3":"Convalescent plasma antibody levels and the risk of death from COVID-19"},{"title3":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial"},{"title3":"Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial"},{"title3":"Early convalescent plasma for high-risk outpatients with COVID-19"},{"title3":"Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019"},{"title3":"Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity"},{"title3":"High frequency of SARS-CoV-2 RNAemia and association with severe disease"},{"title3":"Severe acute respiratory syndrome coronavirus 2 RNA in serum as predictor of severe outcome in coronavirus disease 2019: a retrospective cohort study"},{"title3":"RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients"},{"title3":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients"},{"title3":"Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ. 2020;m4072."}]},{"title2":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","References":[]},{"title2":"An EU programme of COVID-19convalescent plasma collection and transfusion. https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf Accessed on 17 Aug 2020.","References":[]},{"title2":"Guidelines on Clinical Management of COVID-19 v.3. Ministry of Health and Family Welfare; Government of India. 2020. www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf Accessed on 25 Aug 2020.","References":[]},{"title2":"Department of Health and Family Welfare, Ministry of Health and Family Welfare. Government of India. Gazette of India. https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/ Accessed on 25 Aug 2020.","References":[]},{"title2":"Points to consider in the preparation and transfusion of COVID-19 convalescent plasma","References":[{"title3":"Position paper on use of convalescent plasma, serum or immune globulin concentrates as an element in response to an emerging virus"},{"title3":"Donor selection in case of pandemic situations"},{"title3":"Update on transfusion-related acute lung injury"}]},{"title2":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.","References":[]},{"title2":"First isolation of SARS-CoV-2 from clinical samples in India","References":[{"title3":"SARS-associated coronavirus replication in cell lines"},{"title3":"Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Full-genome sequences of the first two SARS-CoV-2 viruses from India"},{"title3":"Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India"},{"title3":"A simple method of estimating fifty per cent endpoints"},{"title3":"Serological and molecular findings during SARS-CoV-2 infection: The first case study in Finland, January to February 2020"},{"title3":"Dengue virus-induced autophagosomes and changes in endomembrane ultrastructure imaged by electron tomography and whole-mount grid-cell culture techniques"},{"title3":"A negative staining method for high resolution electron microscopy of viruses"},{"title3":"Transmission electron microscopy imaging of SARS-CoV-2"},{"title3":"Equine encephalosis virus in India, 2008"},{"title3":"Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to Phlebovirus genus, family Phenuiviridae"},{"title3":"MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets"},{"title3":"On the origin and continuing evolution of SARS-CoV-2"},{"title3":"Isolation and rapid sharing of the 2019 novel coronavirus (SAR-CoV-2) from the first diagnosis of COVID-19 in Australia"},{"title3":"Identification of coronavirus isolated from a patient in Korea with COVID-19"},{"title3":"Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China"},{"title3":"Severe acute respiratory syndrome coronavirus 2 from patient with 2019 novel coronavirus disease"}]},{"title2":"A minimal common outcome measure set for COVID-19 clinical research","References":[{"title3":"Innovation for pandemics"},{"title3":"The critical role of biomedical research in pandemic preparedness"},{"title3":"Clinical trials during epidemics"},{"title3":"Developing core outcome sets for clinical trials: issues to consider"},{"title3":"Core outcome sets and systematic reviews"},{"title3":"International Clinical Trials Registry Platform (ICTRP)"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy"},{"title3":"Clinical characteristics of Covid-19 in New York City"},{"title3":"COVID-19 report: 08 April 2020"},{"title3":"Real estimates of mortality following COVID-19 infection"},{"title3":"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China"},{"title3":"Potential association between COVID-19 mortality and health-care resource availability"},{"title3":"Update: public health response to the coronavirus disease 2019 outbreak:United States, February 24, 2020"},{"title3":"Coronavirus resource center: mortality analyses"},{"title3":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients"},{"title3":"Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing"},{"title3":"Clinical management of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)"},{"title3":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Treating ordinal scales as interval scales: an attempt to resolve the controversy"},{"title3":"Likert scales, levels of measurement and the &quot;laws&quot; of statistics"},{"title3":"Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations"},{"title3":"Outcome measures in rheumatoid arthritis randomised trials over the last 50 years"},{"title3":"Assessing psychiatric impairment in primary care with the Sheehan Disability Scale"},{"title3":"Effects of quantitative ordinal scale design on the accuracy of estimates of mean disease severity"},{"title3":"Global COVID-19: clinical platform: novel coronavius (COVID-19): rapid version"},{"title3":"&quot;Solidarity&quot; clinical trial for COVID-19 treatments"}]},{"title2":"Adverse drug reactions: definitions, diagnosis, and management","References":[]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: challenges for global health governance"},{"title3":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses:a statement of the Coronavirus Study Group"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society"},{"title3":"KDIGO clinical practice guidelines for acute kidney injury"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Chinese management guideline for COVID-19 (version 6.0)"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Predictors of mortality in Middle East respiratory syndrome (MERS)"},{"title3":"Exacerbated innate host response to SARS-CoV in aged non-human primates"},{"title3":"The immunopathogenesis of sepsis in elderly patients"},{"title3":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"},{"title3":"Serial evaluation of the SOFA score to predict outcome in critically ill patients"},{"title3":"Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network"},{"title3":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study"},{"title3":"Acute pneumonia and the cardiovascular system"},{"title3":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis"},{"title3":"Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"D-dimer is a significant prognostic factor in patients with suspected infection and sepsis"},{"title3":"Risk of myocardial infarction and stroke after acute infection or vaccination"},{"title3":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality"},{"title3":"Cardiovascular complications of acute respiratory infections: current research and future directions"},{"title3":"Regulation of ACE2 in cardiac myocytes and fibroblasts"},{"title3":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase"},{"title3":"Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus infection"},{"title3":"Viral load kinetics of MERS coronavirus infection"},{"title3":"Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection"},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients"}]},{"title2":"Computing adjusted risk ratios and risk differences in Stata","References":[]},{"title2":"Effect of convalescent plasma on mortality among hospitalized patients with covid-19: initial three-month experience.","References":[]},{"title2":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","References":[]},{"title2":"Pragmatic Trials","References":[]},{"title2":"Khan J, Hizbullah M, Jain N. Coronavirus pandemic fuels black-market for plasma of recovered patients. India Today July 22, 2020. www.indiatoday.in/india/story/exclusive-coronavirus-pandemic-fuels-black-market-for-plasma-of-recovered-patients-1703332-2020-07-22 Accessed on 25 Aug 2020.","References":[]}]},{"title1":"Convalescent Plasma Treatment Reduced Mortality in Patients With Severe
Pandemic Influenza A (H1N1) 2009 Virus Infection","References":[{"title2":"Delayed decrease of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection","References":[]},{"title2":"Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza","References":[{"title3":"World now at the start of 2009 influenza pandemic"},{"title3":"Severe respiratory disease concurrent with the circulation of H1N1 influenza"},{"title3":"Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection:United States, April-August 2009"},{"title3":"Transmission potential of the new influenza A (H1N1) virus and its age-specificity in Japan"},{"title3":"2009 pandemic influenza A (H1N1) virus infections:Chicago, Illinois, April-July 2009"},{"title3":"Influenza A(H1N1)v in Germany: the first 10,000 cases"},{"title3":"2009 H1N1 flu situation update"},{"title3":"Pandemic (H1N1) 2009:update 67"},{"title3":"Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection"},{"title3":"Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the &quot;PROTECT&quot; phase of the pandemic response"},{"title3":"Clinical attack rate and presentation of pandemic H1N1 influenza versus seasonal influenza A and B in a pediatric cohort in Nicaragua"},{"title3":"Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza viruses:New Zealand, 2009"},{"title3":"Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009"},{"title3":"Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1)v in Spain"},{"title3":"Novel influenza A virus H1N1 and revised specimen submission guidelines in Pennsylvania"},{"title3":"Pulmonary pathological findings of fatal 2009 pandemic influenza A/H1N1 viral infections"},{"title3":"Staphylococcic pneumonia occurring during an epidemic of pneumonia"},{"title3":"A national survey of severe influenza-associated complications among children and adults, 2003-2004"},{"title3":"Influenza pneumonia: a descriptive study"},{"title3":"Asian influenza A in Boston, 1957-1958"},{"title3":"Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection"},{"title3":"Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969"},{"title3":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness"},{"title3":"Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1):United States, May-August 2009"},{"title3":"Antibiotic use after the diagnosis of viral respiratory tract infection in hospitalized adults"},{"title3":"Impact of rapid diagnosis on management of adults hospitalized with influenza"},{"title3":"Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care"},{"title3":"Acute pulmonary embolism"},{"title3":"ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction)"},{"title3":"Influenza in patients with human immuno-deficiency virus infection"},{"title3":"Chest CT findings of influenza virus-associated pneumonia in 12 adult patients"},{"title3":"Chest CT features of community-acquired respiratory viral infections in adult inpatients with lower respiratory tract infections"},{"title3":"H1N1 2009 influenza virus infection during pregnancy in the USA"},{"title3":"Deaths from Asian influenza associated with pregnancy"},{"title3":"Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women"},{"title3":"Influenza occurring in pregnant women"},{"title3":"Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women"},{"title3":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009"},{"title3":"Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants"},{"title3":"Safety of influenza vaccination during pregnancy"},{"title3":"Self-reported influenza vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS) [table]"}]},{"title2":"Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the &quot;PROTECT&quot; phase of the pandemic response","References":[]},{"title2":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis","References":[]},{"title2":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California","References":[]},{"title2":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand","References":[{"title3":"Pandemic (H1N1) 2009. Influenza update- 10 September 2010."},{"title3":"Australian Influenza Surveillance Report No.41, 2010"},{"title3":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand"},{"title3":"Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience"},{"title3":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration"},{"title3":"3101.0 - Australian Demographic statistics, March 2010 "},{"title3":"National population estimates, 2010"},{"title3":"Mortality associated with influenza and respiratory syncytial virus in the United States"},{"title3":"Pandemic (H1N1) 2009 influenza (&quot;swine flu&quot;) in Australian and New Zealand intensive care"},{"title3":"3201.0 - Population by Age and Sex, Australian States and Territories"},{"title3":"Pandemic (H1N1) 2009"},{"title3":"Critically ill patients with 2009 influenza A(H1N1) infection in Canada"},{"title3":"Critically Ill patients with 2009 influenza A(H1N1) in Mexico"},{"title3":"Rescue therapy in adult and pediatric patients with pH1N1 influenza infection: a tertiary center intensive care unit experience from April to October 2009"},{"title3":"Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere"},{"title3":"Hospitalized patients with 2009 H1N1 influenza infection: the Mayo Clinic experience"},{"title3":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California"},{"title3":"Severe respiratory disease concurrent with the circulation of H1N1 influenza"},{"title3":"Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain"},{"title3":"Severe 2009 H1N1 influenza in pregnant and postpartum women in California"},{"title3":"Factors associated with severe disease in hospitalised adults with pandemic (H1N1) 2009 in Spain"},{"title3":"Public Health Surveillance in New Zealand Influenza weekly update - 2010/39: 3 October 2010"},{"title3":"New Zealand Ministry of health Pandemic Influenza H1N12009 - Update 2011"},{"title3":"Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009"},{"title3":"Seroprevalence of the 2009 influenza A (H1N1) pandemic in New Zealand. 2010"},{"title3":"Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009"},{"title3":"Safety and effectiveness of a 2009 H1N1 vaccine in Beijing"},{"title3":"Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection"}]},{"title2":"An epidemiological study of 1348 cases of pandemic H1N1 influenza admitted to Singapore hospitals from July to September 2009","References":[]},{"title2":"Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009","References":[]},{"title2":"Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China","References":[]},{"title2":"Concurrent comparison of epidemiology, clinical presentation outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and seasonal influenza A virus infection","References":[{"title3":"Pandemic versus epidemic influenza mortality: a pattern of changing age distribution"},{"title3":"Severe respiratory disease concurrent with the circulation of H1N1 influenza"},{"title3":"Critical care services and 2009 H1N1 influenza in Australia and New Zealand"},{"title3":"Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza"},{"title3":"Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection:United States, April-August 2009"},{"title3":"Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina"},{"title3":"Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study"},{"title3":"Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the &quot;PROTECT&quot; phase of the pandemic response"},{"title3":"Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the &quot;PROTECT&quot; phase of the pandemic response"},{"title3":"Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR"},{"title3":"The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination"},{"title3":"The distinct clinical profile of chronically critically ill patients: a cohort study"},{"title3":"The natural viral load profile of patients with pandemic swine-origin influenza A H1N1 2009 (pH1N1) and the effect of oseltamivir treatment"},{"title3":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus"},{"title3":"Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections"},{"title3":"Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus"},{"title3":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses"},{"title3":"Recommended composition of influenza virus vaccines for use in the 2010 influenza season (southern hemisphere winter)"},{"title3":"Central nervous system injury-induced immune deficiency syndrome"},{"title3":"Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A (H1N1) disease"},{"title3":"Prevalence of obesity, overweight and underweight in a Hong Kong community: the United Christian Nethersole Community Health Service (UCNCHS) primary health care program 1996-1997"},{"title3":"Pandemic influenza and pregnant women"},{"title3":"Replication of influenza virus in organ cultures of human and simian urogenital tissues and human foetal tissues"},{"title3":"H3N2 influenza A virus replicates in immortalized human first trimester trophoblast cell lines and induces their rapid apoptosis"},{"title3":"Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses"},{"title3":"Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada"},{"title3":"Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians"}]},{"title2":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","References":[]},{"title2":"Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus","References":[]},{"title2":"The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza","References":[]},{"title2":"Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome","References":[]},{"title2":"Hark back: passive immunotherapy for influenza and other serious infections","References":[]},{"title2":"Treatment of Argentine hemorrhagic fever","References":[{"title3":"Protection of Junin virus-infected marmosets by passive administration of immune serum: association with late neurological signs"},{"title3":"Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses"},{"title3":"Fiebre Hemorragica experimental en el cobayo (virus Junin)"},{"title3":"Argentine hemorrhagic fever: alterations of the complement system and anti-Junin virus humoral response"},{"title3":"Pathogenesis of viral hemorrhagic fever"},{"title3":"Potenciales evocados auditivos de tronco cerebral en periodos alejados de la fiebre hemorragica Argentina"},{"title3":"Antiviral treatment of Argentine hemorrhagic fever"},{"title3":"Modificacion de la respuesta humoral especifica en enfermos de FHA tratados con plasma inmune"},{"title3":"Importance of dose of neutralizing antibodies in treatment of Argentine hemorrhagic fever with immune plasma"},{"title3":"Sindrome neurologico tardio en enfermos de Fiebre Hemorragica Argentina tratados con plasma inmune"},{"title3":"Current status of the treatment of Argentine hemorrhagic fever"},{"title3":"Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever"},{"title3":"Enria, D., Bowen, M.D., Mills, J.N., Shieh, W.J., Bausch, D., Peters, C.J., 2004. Arenavirus infections. In: Guerrant, R.L., Walker, D. H., Weller, P.F., Saunders, W.B. (Eds.), Tropical Infectious Diseases: Principles, Pathogens, and Practice, vol. 2, pp. 1191-1212 (Chapter 111)."},{"title3":"Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections"},{"title3":"Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds"},{"title3":"Interferon alfacon-1 protects hamsters from lethal Pichinde virus infection"},{"title3":"Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters"},{"title3":"In vitro and in vivo activity of T-705 against arenavirus and bunyavirus infections"},{"title3":"Experimental Argentine hemorrhagic fever in rhesus macaques: virus-specific variations in pathology"},{"title3":"The gamma globulins and their significance (concluded). IV. Therapeutic uses of gamma globulins"},{"title3":"Increased tumor necrosis factor-levels in Argentine hemorrhagic fever"},{"title3":"Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever"},{"title3":"Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs"},{"title3":"Treatment of Junin virus-infected guinea pigs with immune serum: development of late neurological disease"},{"title3":"Viral strain dependent differences in experimental Argentine hemorrhagic fever (Junin virus) infection of guinea pigs"},{"title3":"Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells"},{"title3":"Endogenous interferon in Argentine hemorrhagic fever"},{"title3":"Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever"},{"title3":"Clinical and epidemiological patterns of Argentine hemorrhagic fever"},{"title3":"Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome"},{"title3":"Systemic disorders in Argentine haemorrhagic fever"},{"title3":"Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever"},{"title3":"Relationship between hematopoietic growth factors levels and hematological parameters in Argentine hemorrhagic fever"},{"title3":"Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response"},{"title3":"Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaques"},{"title3":"Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever"},{"title3":"Coagulation studies in Argentine hemorrhagic fever"},{"title3":"Neutralizacion de la viremia en enfermos de fiebre hemorragica Argentina tratados con plasma inmune"},{"title3":"Passive immunization against poliomyelitis: the hammon gamma globulin field trials, 1951-1953"},{"title3":"Antiviral effect of ribavirin on Junin virus replication in vitro"},{"title3":"Fiebre hemorragica Argentina. Formas clin."},{"title3":"Tratamiento de la Fiebre Hemorragica Argentina. Uso de plasma de convalecientes y drogas inmunosupresoras"},{"title3":"Prevalencia de anticuerpos para el virus de la Hepatitis C en donantes de plasma para el tratamiento de la Fiebre Hemorragica Argentina"},{"title3":"Lymphocyte subsets alteration in patients with Argentine hemorrhagic fever"},{"title3":"Accion de los inmunosueros en la fiebre hemorragica experimental"},{"title3":"Effect of ribavirin and immune serum on Junin virus-infected primates"},{"title3":"Therapeutic effect of the antiviral agent ribavirin in Junin virus infection of primates"}]},{"title2":"Parvovirus B19 infection in pediatric transplant patients","References":[{"title3":"Viral surveillance and subclinical viral infection in pediatric kidney transplantation"},{"title3":"Viral Infection in Renal Transplant Recipients"},{"title3":"Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort"},{"title3":"Viral infection after renal transplantation: Surveillance and management"},{"title3":"Signs and Symptoms of Cytomegalovirus Disease in Kidney Transplant Recipients"},{"title3":"Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement"},{"title3":"Detection of Viral DNA in kidney graft preservation and washing solutions Is Predictive of Posttransplant Infections in Pediatric Recipients"},{"title3":"BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies"},{"title3":"Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients"},{"title3":"Post-transplant lymphoproliferative disease"},{"title3":"Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review"},{"title3":"Late-acute renal allograft rejection and symptomless cytomegalovirus infection"},{"title3":"Persistent BK viremia Does Not Increase Intermediate-Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies"},{"title3":"Association between Epstein-Barr virus infection and Late Acute Transplant Rejection in Long-Term Transplant Patients"},{"title3":"Parvovirus Infection-Related Anemia after Kidney Transplantation"},{"title3":"Epidemiology of parvovirus B19 and anemia among kidney transplant recipients: A meta-analysis"},{"title3":"Parvovirus B19 and the Kidney"},{"title3":"Investigation of intrarenal viral Infections in Kidney Transplant Recipients Unveils an Association between Parvovirus B19 and Chronic Allograft Injury"},{"title3":"Parvovirus B19 infection after Transplantation: A Review of 98 Cases"},{"title3":"Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients"},{"title3":"Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series"},{"title3":"Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients"},{"title3":"Thrombotic Microangiopathy Associated with Parvovirus B 19 Infection after Renal Transplantation"},{"title3":"Antibody-mediated Enhancement of Parvovirus B19 Uptake into Endothelial Cells Mediated by a Receptor for Complement Factor C1q"},{"title3":"Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein"},{"title3":"Molecular Mechanisms of IFN-gamma to Up-Regulate MHC Class I Antigen Processing and Presentation"},{"title3":"Designing of interferon-gamma inducing MHC class-II binders"},{"title3":"Endothelial Progenitor Cells Possess Monocyte-like Antigen-presenting and T-cell-Co-stimulatory Capacity"},{"title3":"Blocking MHC class II on human endothelium mitigates acute rejection"},{"title3":"Donor-Derived Human Parvovirus B19 Infection in Kidney Transplantation"},{"title3":"The AST Infectious Diseases Community of Practice Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice"},{"title3":"Intravenous immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature"},{"title3":"Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"},{"title3":"Acute rejection and graft survival in renal transplanted patients with viral diseases"},{"title3":"BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection"},{"title3":"Increasing net immunosuppression after BK polyoma virus infection"},{"title3":"Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction"},{"title3":"De novo donor-specific antibody following BK nephropathy: The incidence and association with antibody-mediated rejection"},{"title3":"The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology"},{"title3":"Measurement and Estimation of Glomerular Filtration Rate in Children"},{"title3":"Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability"},{"title3":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the Europe an Tacrolimus Multicenter Renal Study Group"},{"title3":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK506 Kidney Transplant Study Group"},{"title3":"One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient"},{"title3":"Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation"},{"title3":"Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives"},{"title3":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. Special Issue: KDIGO clinical Practice Guideline for the Care of Kidney Transplant Recipients"},{"title3":"Human parvovirus B19 in bone marrows from adults with acquired immunodeficiency syndrome: A comparative study using in situ hybridization and immunohistochemistry"},{"title3":"De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury"}]},{"title2":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","References":[]},{"title2":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","References":[]},{"title2":"Treatment with convalescent plasma for influenza A (H5N1) infection","References":[]},{"title2":"Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza","References":[]},{"title2":"Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic","References":[{"title3":"What is the optimal therapy for patients with H5N1 influenza?"},{"title3":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?"},{"title3":"Treatment with convalescent plasma for influenza A (H5N1) infection"},{"title3":"Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza"},{"title3":"Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic"},{"title3":"Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States"},{"title3":"Mitigation strategies for pandemic influenza in the United States"},{"title3":"Pandemic potential of a strain of influenza A (H1N1): early findings"},{"title3":"Transmission potential of the new influenza A(H1N1) virus and its agespecificity in Japan"},{"title3":"The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus"},{"title3":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009"}]},{"title2":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus","References":[]},{"title2":"The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment","References":[{"title3":"Human infection with new influenza A (H1N1) virus: clinical observations from Mexico and other affected countries, May 2009"},{"title3":"Statement to the press by WHO Director-General Dr Margaret Chan June 11 2009 World now at the start of 2009 influenza pandemic"},{"title3":"Update: novel influenza A (H1N1) virus infection-Mexico, March-May, 2009"},{"title3":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus"},{"title3":"Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice"},{"title3":"Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets"},{"title3":"Emergence and pandemic potential of swine-origin H1N1 influenza virus"},{"title3":"Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico"},{"title3":"WHO Guidelines for pharmacological management of pandemic (H1N1 2009 influenza and other influenza virus"},{"title3":"Interim guidance on antiviral treatment, chemoprophylaxis and pneumococcal vaccination for human swine influenza (HSI)/influenza A (H1N1) infection"},{"title3":"CDC Health Alert Network (HAN) Info Service Message: Three reports of oseltamivir-resistant novel influenza A (H1N1) viruses"},{"title3":"Avian influenza virus infections in humans"},{"title3":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial"},{"title3":"Antiviral therapy for respiratory tract infections"},{"title3":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis"},{"title3":"Prevention and control of human swine influenza infection in Hong Kong"},{"title3":"Strategy and management of human swine influenza (HSI)"},{"title3":"Interim guidance on antiviral treatment, chemoprophylaxis and pneumococcal vaccination for human swine influenza (HSI) / influenza A (H1N1) infection"},{"title3":"Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome"},{"title3":"Predicting influenza infections during epidemics with use of a clinical case definition"},{"title3":"Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza"},{"title3":"Comparison of the NucliSens easyMAG and Qiagen BioRobot 9604 nucleic acid extraction systems for detection of RNA and DNA respiratory viruses in nasopharyngeal aspirate samples"},{"title3":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus"},{"title3":"Medical treatment of viral pneumonia including SARS in immunocompetent adult"},{"title3":"Centers for Disease Control and Prevention (CDC). CDC Realtime RT-PCR (rRTPCR) protocol for detection and characterization of influenza (version 2007), CDC REF. # I-007-05"},{"title3":"Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses"},{"title3":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment"},{"title3":"Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors"},{"title3":"Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season"},{"title3":"Oseltamivir resistance during treatment of influenza A (H5N1) infection"},{"title3":"Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus"},{"title3":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study"},{"title3":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08"},{"title3":"Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009"},{"title3":"Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons"},{"title3":"Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China"},{"title3":"Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity"},{"title3":"Fatal co-infection with swine origin influenza virus A/H1N1 and community-acquired methicillin-resistant Staphylococcus aureus"},{"title3":"The severe acute respiratory syndrome (SARS)"},{"title3":"Viral loads in clinical specimens and SARS manifestations"},{"title3":"Functional tumor necrosis factor-related apoptosis-inducing ligand production by avian influenza virus-infected macrophages"},{"title3":"Clinical findings and demographic factors associated with intensive care unit admission in Utah due to novel 2009 influenza A(H1N1) infection"},{"title3":"Hospitalized patients with novel influenza A (H1N1) virus infection - California, April - May, 2009"},{"title3":"Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses"},{"title3":"Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients"},{"title3":"Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey"},{"title3":"Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review"},{"title3":"Influenza associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir"}]},{"title2":"Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection","References":[]},{"title2":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009","References":[]},{"title2":"Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR","References":[]},{"title2":"Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice","References":[{"title3":"Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus"},{"title3":"Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus"},{"title3":"A pandemic warning?"},{"title3":"Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia"},{"title3":"Avian influenza H5N1 in tigers and leopards"},{"title3":"Avian H5N1 influenza in cats"},{"title3":"Global task force for influenza"},{"title3":"Confronting the avian influenza threat: vaccine development for a potential pandemic"},{"title3":"Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines"},{"title3":"From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza"},{"title3":"Avian Influenza A (H5N1) in 10 Patients in Vietnam"},{"title3":"Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice"},{"title3":"Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection"},{"title3":"Avian flu: Isolation of drug-resistant H5N1 virus"},{"title3":"Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses"},{"title3":"Antibodies for the prevention and treatment of viral diseases"},{"title3":"Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments"},{"title3":"A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro"},{"title3":"Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains"},{"title3":"Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice"},{"title3":"Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model"},{"title3":"Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines"},{"title3":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion"},{"title3":"Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries"},{"title3":"The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression"},{"title3":"Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control"},{"title3":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin"},{"title3":"Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation"},{"title3":"The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)"},{"title3":"H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes"},{"title3":"Monoclonal and recombinant antibodies, 30 years after"},{"title3":"Strategies for containing an emerging influenza pandemic in Southeast Asia"},{"title3":"Containing Pandemic Influenza at the Source"},{"title3":"Antigen distortion allows influenza virus to escape neutralization"},{"title3":"Structure of influenza virus haemagglutinin complexed with a neutralizing antibody"}]},{"title2":"Acute renal impairment in coronavirus-associated severe acute respiratory syndrome","References":[{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study"},{"title3":"World Health Organization: Case definitions for surveillance of severe acute respiratory syndrome (SARS). http://www.who.int/csr/sars/infectioncontrol (revised May 1, 2003, and accessed May 10, 2003)"},{"title3":"The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination"},{"title3":"Tissue and cellular tropisms of the coronavirus associated with severe acute respiratory syndrome:An in-situ hybridization study of fatal cases"},{"title3":"Severe acute respiratory syndrome: Clinical outcome and prognostic correlates"},{"title3":"Development of a standard treatment protocol for severe acute respiratory syndrome"},{"title3":"Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection"},{"title3":"Severe acute respiratory syndrome in haemodialysis patients: A report of two cases"},{"title3":"Severe acute respiratory syndrome in a haemodialysis patient"},{"title3":"The clinical presentation and outcome of severe acute respiratory syndrome in dialysis patients"},{"title3":"Clinical, laboratory, and radiologic manifestation of SARS"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area"}]},{"title2":"The infection attack rate and severity of 2009 pandemic influenza (H1N1) in Hong Kong","References":[]},{"title2":"Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence","References":[]},{"title2":"Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China","References":[{"title3":"Swine influenza A (H1N1) infection in two children:southern California, March-April 2009."},{"title3":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic."},{"title3":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans."},{"title3":"Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice."},{"title3":"Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine."},{"title3":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08."},{"title3":"Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR."},{"title3":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study."},{"title3":"Avian flu: isolation of drug-resistant H5N1 virus."},{"title3":"Oseltamivir resistance during treatment of influenza A (H5N1) infection."},{"title3":"Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility."},{"title3":"The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo."},{"title3":"In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675."},{"title3":"Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo."}]},{"title2":"Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts","References":[{"title3":"Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009"},{"title3":"Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009"},{"title3":"Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009"},{"title3":"Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis"},{"title3":"The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza"},{"title3":"Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir"},{"title3":"Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors"},{"title3":"A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus"},{"title3":"Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child"},{"title3":"Rapid Selection of a Transmissible Multi-Drug Resistant Influenza A/H3N2 Virus in an Immunocomrpomised Host"},{"title3":"Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift"},{"title3":"Universal primer set for the full-length amplification of all influenza A viruses"},{"title3":"Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants"},{"title3":"Position statement: global neuraminidase inhibitor susceptibility network"},{"title3":"Pandemic and seasonal influenza: therapeutic challenges"}]},{"title2":"Identification of influenza A nucleoprotein as an antiviral target","References":[{"title3":"Centers for Disease Control and Prevention. http://www.cdc.gov/flu/avianflu/avian-in-humans.htm. Accessed 15 June 2016."},{"title3":"Centers for Disease Control and Prevention. http://www.cdc.gov/flu/about/viruses/transmission.htm. Accessed 15 June 2016."},{"title3":"Emergence and pandemic potential of swine-origin H1N1 influenza virus"},{"title3":"Centers for Disease Control and Prevention. http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm. Accessed 15 June 2016."},{"title3":"Centers for Disease Control and Prevention. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html. Accessed 15 July 2016."},{"title3":"Hunter JC, Rodriguez DC, Aragon TJ. Public health management of antiviral drugs during the 2009 H1N1 influenza pandemic: a survey of local health departments in California. BMC Public Health. 2012;12(82). doi: 10.1186/1471-2458-12-82."},{"title3":"Centers for Disease Control and Prevention. http://www.cdc.gov/flu/pastseasons/1314season.htm. Accessed 15 June 2016."},{"title3":"Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus"},{"title3":"Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets"},{"title3":"Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis"},{"title3":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study"},{"title3":"Davis AM, Chabolla BJ, Newcomb LL. Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex. Virol J. 2014;1(167). doi:10.1186/1743-422X-11-167."},{"title3":"Influenza viruses and mRNA splicing: doing more with less"},{"title3":"A novel influenza A virus mitochondrial protein that induces cell death"},{"title3":"A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA"},{"title3":"An overlapping protein-coding region in influenza A virus segment 3 modulates the host response"},{"title3":"Identification of novel influenza A virus proteins translated from PA mRNA"},{"title3":"The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits"},{"title3":"A unique cap (m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription"},{"title3":"Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site"},{"title3":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit"},{"title3":"Direct evidence that the poly (A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template"},{"title3":"Interaction of the influenza a virus nucleocapsid protein with the viral RNA polymerase potentiates unprimed viral RNA replication"},{"title3":"The influenza A virus NS1 protein interacts with the nucleoprotein of viral ribonucleoprotein complexes"},{"title3":"An influenza replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesis"},{"title3":"Nuclear factor 90 negatively regulates influenza virus replication by interaction with the viral nucleoprotein"},{"title3":"Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis"},{"title3":"Replication-coupled and host factor-mediated encapsidation of the influenza virus genome by viral nucleoprotein"},{"title3":"The cellular RNA helicase UAP56 is required for prevention of double-stranded RNA formation during influenza A virus infection"},{"title3":"Large-scale analysis of influenza A virus nucleoprotein sequence conservation reveals potential drug-target sites"},{"title3":"Biochemical and structural evidence in support of a coherent model for the formation of the double-helical influenza A virus ribonucleoprotein"},{"title3":"The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA"},{"title3":"Identification of influenza A nucleoprotein as an antiviral target"},{"title3":"E339... R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors"},{"title3":"Influenza virus nucleoprotein interacts with influenza virus polymerase proteins"},{"title3":"Mutations to PB2 and NP proteins of an avian influenza virus combine to confer efficient growth in primary human respiratory cells"},{"title3":"The structure of a biologically active influenza virus ribonucleoprotein complex"},{"title3":"Sanchez A, Guerrero-Juarez CF, Ramirez,J, Newcomb LL. Nuclear localized Influenza nucleoprotein N-terminal deletion mutant is deficient in functional vRNP formation. Virol J. 2014;11(1). doi:10.1186/1743-422X-11-155."},{"title3":"Bleach gel: a simple agarose gel for analyzing RNA quality"},{"title3":"Influenza Research Database. www.fludb.org. Accessed 15 Jan 2017."}]},{"title2":"Host defense mechanisms against influenza virus: interaction of influenza virus with murine macrophages in vitro","References":[]},{"title2":"Neutralization of human respiratory syncytial virus infectivity by antibodies low molecular weight compounds targeted against the fusion (F) glycoprotein","References":[]}]},{"title1":"Retrospective comparison of convalescent plasma with continuing high?dose methylprednisolone treatment in SARS patients","References":[{"title2":"A major outbreak of severe acute respiratory syndrome in Hong Kong","References":[]},{"title2":"A novel coronavirus associated severe acute respiratory syndrome","References":[{"title3":"Ahmadi KS, Vahabizad F, Banihashemi G, Sahraian MA,  Gheini MR, Eslami M, Marhamati H, Mirhadi MS (2020) Ischemic stroke in patients with COVID-19 disease: a report of 10 cases from Iran Cerebrovasc Dis 1-6 10.1159/000513279"},{"title3":"Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19"},{"title3":"COVID-19 infection recurrence presenting with meningoencephalitis"},{"title3":"Matos AR, Quintas-Neves M, Oliveira AI, Dias L, Marques S, Carvalho R, Alves JN (2020) COVID-19 associated central nervous system vasculopathy Can J Neurol Sci 1-6 10.1017/cjn.2020.1092020.1092020.1092020.109"},{"title3":"Focal cerebral arteriopathy in a COVID-19 pediatric patient"},{"title3":"An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19"},{"title3":"A first case of meningitis/encephalitis associated with SARS-Coronavirus-2"},{"title3":"COVID-19, SARS and MERS: a neurological perspective"},{"title3":"Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): a review"},{"title3":"A review of Coronavirus Disease-2019 (COVID-19)"},{"title3":"Neurological manifestations in severe acute respiratory syndrome"},{"title3":"Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses Brain Behav Immun 18-22 10.1016/j.bbi.2020.03.0312020.03.0312020.03.0312020.03.031"},{"title3":"Encephalitis as a clinical manifestation of COVID-19"},{"title3":"Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in adults-a case report and literature review"}]},{"title2":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","References":[]},{"title2":"Severe acute respiratory syndrome","References":[]},{"title2":"Update: severe acute respiratory syndrome","References":[{"title3":"ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2"},{"title3":"Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta-regression analyzing influencing factors"},{"title3":"The PRONTO study: clinical performance of ID NOW in individuals with compatible SARS-CoV-2 symptoms in walk-in centres-accelerated turnaround time for contact tracing"},{"title3":"Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19"},{"title3":"Diagnostic accuracy of SARS-CoV-2 antigen detection test in children: a real-life study"},{"title3":"Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients: results of a Prospective Comparative Trial (RESTART)"},{"title3":"Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19"},{"title3":"Time-course evaluation of the quantitative antigen test for severe acute respiratory syndrome coronavirus 2: the potential contribution to alleviating isolation of COVID-19 patients"},{"title3":"Performance of a rapid SARS-CoV-2 antigen detection assay in symptomatic children"},{"title3":"The value of rapid antigen tests for identifying carriers of viable SARS-CoV-2"},{"title3":"Field evaluation of specificity and sensitivity of a standard SARS-CoV-2 antigen rapid diagnostic test: a prospective study at a teaching hospital in Northern Ghana"},{"title3":"Detection of SARS-CoV-2 by antigen ELISA test is highly swayed by viral load and sample storage condition"},{"title3":"Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South Africa"},{"title3":"Field evaluation of a rapid antigen test (PanBioTM COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres"},{"title3":"Analytical and clinical performance of the PanBio COVID-19 antigen-detecting rapid diagnostic test"},{"title3":"Evaluation of clinical utility of novel coronavirus antigen detection reagent, Espline  SARS-CoV-2"},{"title3":"Clinical validation of an open-access SARS-COV-2 antigen detection lateral flow assay, compared to commercially available assays"},{"title3":"Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection"},{"title3":"Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study"},{"title3":"Evaluation of the PanBioTM rapid antigen test for SARS-CoV-2 in primary health care centers and test sites"},{"title3":"Performance of the Wondfo 2019-nCoV antigen test using self-collected nasal versus professional-collected nasopharyngeal swabs in symptomatic SARS-CoV-2 infection"},{"title3":"Implementing SARS-CoV-2 rapid antigen testing in the emergency ward of a Swiss University Hospital: the INCREASE Study"},{"title3":"Urgent need of rapid tests for SARS CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2"},{"title3":"High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection"},{"title3":"Implementation of the Abbott ID Now COVID-19 assay at a tertiary care center: a prospective pragmatic implementation study during the third wave of SARS-CoV-2 in Ontario"},{"title3":"A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: a clinical performance study"},{"title3":"The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing"},{"title3":"Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children"},{"title3":"Diagnostic accuracy of rapid antigen test for COVID-19 in an emergency department"},{"title3":"Diagnostic utility and performance of rapid antigen test in SARS CoV-2 in symptomatic and asymptomatic patients during the second pandemic wave in Kashmir, North India"},{"title3":"Evaluation of the PanBio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19"},{"title3":"COVID-19 rapid antigen test at hospital admission associated to the knowledge of individual risk factors allow overcoming the difficulty of managing suspected patients in hospitals COVID-19 rapid antigen test facilitates the management of suspected patients on hospital admission"},{"title3":"COVID-19 test directory - FIND"},{"title3":"Analytical performance of the point-of-care BIOSYNEX COVID-19 Ag BSS for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective field evaluation during the COVID-19 third wave in France"},{"title3":"Fourati S, Audureau E, Chevaliez S, Pawlotsky J-M. Evaluation de la performance diagnostique des tests rapides d'orientation diagnostique antigeniques COVID-19. n.d. https://www.calameo.com/read/004021827da342e75785b?utm_source=platform&amp;utm_medium=email&amp;utm_campaign=book_created&amp;utm_content=html&amp;utm_term=4021827 [Accessed 15 August 2022]."},{"title3":"Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration"},{"title3":"Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil"},{"title3":"Analytical performances of the COVISTIXTM antigen rapid test for SARS-CoV-2 detection in an unselected population (all-comers)"},{"title3":"Think of the children: evaluation of SARS-CoV-2 rapid antigen test in pediatric population"},{"title3":"Rapid chromatographic immunoassay-based evaluation of COVID-19: a cross-sectional, diagnostic test accuracy study &amp; its implications for COVID-19 management in India"},{"title3":"An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients"},{"title3":"SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona Campus"},{"title3":"Use of immunochromatographic SARS-CoV-2 antigen testing in eight long-term care facilities for the elderly"},{"title3":"Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings"},{"title3":"Evaluation of the PanBio SARS-CoV-2 rapid antigen detection test in the Bahamas"},{"title3":"Diagnostic accuracy of the PanBioTM COVID-19 antigen rapid test device for SARS-CoV-2 detection in Kenya, 2021: a field evaluation"},{"title3":"Accuracy of saliva and nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric cohort study"},{"title3":"Clinical evaluation of the rapid STANDARD Q COVID-19 Ag test for the screening of severe acute respiratory syndrome coronavirus 2"},{"title3":"Validation of the PanBioTM COVID-19 antigen rapid test (Abbott) to screen for SARS-CoV-2 infection in Sint Maarten: a diagnostic accuracy study"},{"title3":"Prospective analytical performance evaluation of the QuickNaviTM-COVID19 Ag for asymptomatic individuals"},{"title3":"Comparison of antigen tests and qPCR in rapid diagnostics of infections caused by SARS-CoV-2 virus"},{"title3":"Clinical evaluation of rapid point-of-care antigen tests for diagnosis of SARS-CoV-2 infection"},{"title3":"Validation and implementation of the PanBio COVID-19 Ag rapid test for the diagnosis of SARS-CoV-2 infection in symptomatic hospital healthcare workers"},{"title3":"Assessment of SARS-CoV-2 infectivity by a rapid antigen detection test"},{"title3":"The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2-evaluation of the accuracy and ease-of-use"},{"title3":"The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2"},{"title3":"Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting"},{"title3":"Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort"},{"title3":"Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)"},{"title3":"PanBio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms"},{"title3":"Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab"},{"title3":"Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test"},{"title3":"Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples"},{"title3":"Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease"},{"title3":"Nasopharyngeal PanBio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age"},{"title3":"Analytical performances of the point-of-care SIENNATM COVID-19 antigen rapid test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective evaluation during the COVID-19 second wave in France"},{"title3":"SARS-CoV-2 antigen detection to expand testing capacity for COVID-19: results from a hospital emergency department testing site"},{"title3":"Multicenter evaluation of the PanBioTM COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection"},{"title3":"Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context"},{"title3":"Point of care testing using rapid automated antigen testing for SARS-COV-2 in care homes - an exploratory safety, usability and diagnostic agreement evaluation"},{"title3":"Value of rapid antigen test in comparison with reverse transcriptase-polymerase chain reaction method in the diagnosis of COVID-19"},{"title3":"SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department"},{"title3":"Oral saliva swab reverse transcription PCR for Covid-19 in the paediatric population"},{"title3":"SARS-CoV-2 rapid antigen test: high sensitivity to detect infectious virus"},{"title3":"On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic"},{"title3":"Diagnostic performance of CerTest and PanBio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection"},{"title3":"Comparison of the rapid antigen testing method with RT-qPCR for the diagnosis of COVID-19"},{"title3":"Rapid SARS-CoV-2 antigen detection by immunofluorescence-a new tool to detect 1 infectivity 2 3"},{"title3":"Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples"},{"title3":"Diagnostic accuracy of loop-mediated isothermal amplification coupled to nanopore sequencing (LamPORE) for the detection of SARS-CoV-2 infection at scale in symptomatic and asymptomatic populations"},{"title3":"Real world performance of SARS-CoV-2 antigen rapid diagnostic tests in various clinical settings"},{"title3":"Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia"},{"title3":"Limitations of molecular and antigen test performance for SARS-CoV-2 in symptomatic and asymptomatic COVID-19 contacts"},{"title3":"Diagnostic accuracy and feasibility of a rapid SARS-CoV-2 antigen test in general practice-a prospective multicenter validation and implementation study"},{"title3":"Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial"},{"title3":"Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis"},{"title3":"Clinical evaluation of Sofia Rapid Antigen Assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among emergency department to hospital admissions"},{"title3":"Clinical performance of the Abbott PanBio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19"},{"title3":"Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant"},{"title3":"Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with nasopharyngeal samples"},{"title3":"Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study"},{"title3":"The evaluation of a newly developed antigen test (QuickNaviTM-COVID19 Ag) for SARS-CoV-2: a prospective observational study in Japan"},{"title3":"Clinical application of a new SARS-CoV-2 antigen detection kit (colloidal gold) in the detection of COVID-19"},{"title3":"Evaluation of PanBio rapid antigen test for SARS-CoV-2 in symptomatic patients and their contacts: a multicenter study"},{"title3":"Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients"},{"title3":"Point-of-care evaluation of a rapid antigen test (CLINITEST  Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals"},{"title3":"Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant"},{"title3":"Real world clinical performance of SARS-CoV-2 rapid antigen tests in suspected COVID-19 cases in Taiwan"},{"title3":"Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study"},{"title3":"Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission"},{"title3":"Diagnostic accuracy of the PanBio SARS-CoV-2 antigen rapid test compared with Rt-Pcr testing of nasopharyngeal samples in the pediatric population"},{"title3":"Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium"},{"title3":"Utility of the antigen test for coronavirus disease 2019: factors influencing the prediction of the possibility of disease transmission"},{"title3":"SARS-CoV-2 diagnostic tests: algorithm and field evaluation from the near patient testing to the automated diagnostic platform"},{"title3":"Performance of qualitative and quantitative antigen tests for SARS-CoV-2 using saliva"},{"title3":"Performance of qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva"},{"title3":"Utility of SARS-CoV-2 rapid antigen testing for patient triage in the emergency department: a clinical implementation study in Melbourne, Australia"},{"title3":"Clinical evaluation of BD VeritorTM SARS-CoV-2 and Flu A+B assay for point-of-care (POC) system"},{"title3":"Accuracy of 2 rapid antigen tests during 3 phases of SARS-CoV-2 variants"},{"title3":"Antigen test performance among children and adults at a SARS-CoV-2 community testing site"},{"title3":"Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees"},{"title3":"Performance of antigen testing for diagnosis of COVID-19: a direct comparison of a lateral flow device to nucleic acid amplification based tests"},{"title3":"Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public setting"},{"title3":"Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen from SARS-CoV-2"},{"title3":"Repeated antigen testing among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)-positive nursing home residents"},{"title3":"Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter?"},{"title3":"Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR"},{"title3":"[Usefulness of the antigen for diagnosing SARS-CoV-2 infection in patients with and without symptoms]"},{"title3":"Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts"},{"title3":"Performance and operational evaluation of the access Bio CareStart rapid antigen test in a high-throughput drive-through community testing site in Massachusetts"},{"title3":"Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020"},{"title3":"Comparative evaluation of rapid isothermal amplification and antigen assays for screening testing of SARS-CoV-2"},{"title3":"A prospective diagnostic evaluation of accuracy of self-taken and healthcare worker-taken swabs for rapid COVID-19 testing"},{"title3":"Limits and opportunities of SARS-CoV-2 antigen rapid tests: an experienced-based perspective"},{"title3":"Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an Omicron surge : a cross-sectional study"},{"title3":"Performance of repeat BinaxNOW severe acute respiratory syndrome coronavirus 2 antigen testing in a community setting, Wisconsin, November 2020-December 2020"},{"title3":"Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: implications for screening in a school setting"},{"title3":"High sensitivity and NPV for BinaxNOW rapid antigen test in children at a mass testing site during prevalent Delta variant period"},{"title3":"Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients"},{"title3":"An assessment of a rapid SARS-CoV-2 antigen test in Bangladesh"},{"title3":"Evaluation of performance of the BD Veritor SARS-CoV-2 chromatographic immunoassay test in patients with symptoms of COVID-19"},{"title3":"Assessment of the diagnostic performance of a novel SARS-CoV-2 antigen sealing tube test strip (colloidal gold) as point-of-care surveillance test"},{"title3":"Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture"},{"title3":"Performance evaluation of STANDARD Q COVID-19 Ag home test for the diagnosis of COVID-19 during early symptom onset"},{"title3":"Performance evaluation of a SARS-CoV-2 rapid antigen test: test performance in the community in The Netherlands"},{"title3":"Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test"},{"title3":"Diagnostic performance of rapid antigen test for COVID-19 and the effect of viral load, sampling time, subject's clinical and laboratory parameters on test accuracy"},{"title3":"Role of COVID antigen in the diagnosis of COVID positive in obstetric patients"},{"title3":"Rapid screening of SARS-CoV-2 infection: good performance of nasopharyngeal and Nasal Mid-Turbinate swab for antigen detection among symptomatic and asymptomatic individuals"},{"title3":"Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2"},{"title3":"Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting"},{"title3":"Clinical evaluation of a new antigen-based COVID-19 rapid diagnostic test from symptomatic patients"},{"title3":"A prospective clinical evaluation of the diagnostic accuracy of the SARS-CoV-2 rapid antigen test using anterior nasal samples"},{"title3":"Diagnostic performance of an antigen test with RT-PCR for the detection of SARS-CoV-2 in a hospital setting - Los Angeles County, California, June-August 2020"},{"title3":"Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDxTM: an antigen-detecting point-of-care device for SARS-CoV-2"},{"title3":"Performance of a SARS-CoV-2 antigen rapid immunoassay in patients admitted to the emergency department"},{"title3":"Performance of SARS-CoV-2 antigen testing in symptomatic and asymptomatic adults: a single-center evaluation"},{"title3":"Head-to-head comparison of the accuracy of saliva and nasal rapid antigen SARS-CoV-2 self-testing: cross-sectional study"},{"title3":"Implementation and accuracy of BinaxNOW rapid antigen COVID-19 test in asymptomatic and symptomatic populations in a high-volume self-referred testing site"},{"title3":"Performance of the Diasorin SARS-CoV-2 antigen detection assay on the LIAISON XL"},{"title3":"Evaluation of the rapid antigen test PanBio COVID-19 in saliva and nasal swabs in a population-based point-of-care study"},{"title3":"Performance characteristics of the Abbott BinaxNOW SARS-CoV-2 antigen test in comparison to real-time reverse transcriptase PCR and viral culture in community testing sites during November 2020"},{"title3":"Performance of the LumiraDx microfluidic immunofluorescence point-of-care SARS-CoV-2 antigen test in asymptomatic adults and children"},{"title3":"Role of rapid antigen testing in population-based SARS-CoV-2 screening"},{"title3":"Antigen vs RT-PCR tests for screening quarantined students in Florida during the COVID-19 pandemic SARS-CoV-2 Delta variant surge"},{"title3":"Utility of COVID-19 antigen testing in the emergency department"},{"title3":"Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study"},{"title3":"Point-of-care antigen test for SARS-CoV-2 in asymptomatic college students"},{"title3":"Evaluation of a rapid antigen test (PanBioTM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients"},{"title3":"Analysis of the diagnostic accuracy of rapid antigenic tests for detection of SARS-CoV-2 in hospital outbreak situation"},{"title3":"Diagnostic accuracy of the Abbott ID NOW SARS-CoV-2 rapid test for the triage of acute medical admissions"},{"title3":"The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients"},{"title3":"Low sensitivity of SARS-CoV-2 rapid antigen self-tests under laboratory conditions"},{"title3":"Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: testing frequency and public health messaging is key"},{"title3":"Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values"},{"title3":"Implementation study of SARS-CoV-2 antigen lateral flow tests in men's professional (Premiership) rugby union sports squads in England during the COVID-19 pandemic"},{"title3":"Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study"},{"title3":"Pre-operative SARS CoV-2 rapid antigen test and reverse transcription polymerase chain reaction: a conundrum in surgical decision making"},{"title3":"Limited sensitivity of a rapid SARS-CoV-2 antigen detection assay for surveillance of asymptomatic individuals in Thailand"},{"title3":"Performance characteristics of BinaxNOW COVID-19 antigen card for screening asymptomatic individuals in a university setting"},{"title3":"SARS-CoV-2 rapid antigen testing for departing passengers at Vancouver International Airport"},{"title3":"Sensitivity and specificity of lateral flow antigen test kits for COVID-19 in asymptomatic population of quarantine centre of province 3"},{"title3":"Usefulness of rapid antigen testing for SARS-CoV-2 screening of healthcare workers: a pilot study"},{"title3":"Utility of antigen-based rapid diagnostic test for detection of SARS-CoV-2 virus in routine hospital settings"},{"title3":"Application of SARS-CoV-2 antigenic test in asymptomatic workers: sensitivity and specificity of the test"},{"title3":"Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison"},{"title3":"Development and performance verification of colloidal gold labeled SARS-CoV-2 antigen detection method for routine popular screening of COVID-19 with clinical samples in Poland and China"},{"title3":"Comparison between nasal and nasopharyngeal swabs for SARS-CoV-2 rapid antigen detection in an asymptomatic population, and direct confirmation by RT-PCR from the residual buffer"},{"title3":"Performance of lateral flow assays for SARS-CoV-2 compared to RT-qPCR"},{"title3":"Rapid antigen detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in women admitted for delivery"},{"title3":"Diagnostic performance and clinical application of preoperative COVID-19 bedside testing with ID NOWTM"},{"title3":"Prince-Guerra JL, Almendares O, Nolen LD, Gunn JKL, Dale AP, Buono SA, et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70:100-105."},{"title3":"Comparison of the Quidel sofia SARS FIA test to the Hologic aptima SARS-CoV-2 TMA test for diagnosis of COVID-19 in symptomatic outpatients"},{"title3":"Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: A preliminary report"}]},{"title2":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","References":[]},{"title2":"Prospective study of the clinical progression and viral load of SARS associated coronavirus pneumonia in a community outbreak","References":[{"title3":"multi-country outbreak:update 34"},{"title3":"SARS coronavirus sequencing"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Identification of severe acute respiratory syndrome in Canada"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"Atypical pneumonia"},{"title3":"Guideline on management of severe acute respiratory syndrome (SARS)"},{"title3":"HA guidelines on severe acute respiratory syndrome"},{"title3":"The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination"},{"title3":"APACHE II: a severity of disease classification system"},{"title3":"Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)"},{"title3":"Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus acute respiratory distress syndrome"},{"title3":"Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response"},{"title3":"Prevention of experimental coronavirus colds with intranasal alpha-2b interferon"},{"title3":"Radiological appearances of cytomegalovirus infections"},{"title3":"A case of influenza bronchiolitis complicated by pneumomediastinum and subcutaneous emphysema"}]}]}]}